<SEC-DOCUMENT>0001213900-26-055211.txt : 20260512
<SEC-HEADER>0001213900-26-055211.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512172416
ACCESSION NUMBER:		0001213900-26-055211
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amesite Inc.
		CENTRAL INDEX KEY:			0001807166
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-PREPACKAGED SOFTWARE [7372]
		ORGANIZATION NAME:           	06 Technology
		EIN:				823431717
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295814
		FILM NUMBER:		26969967

	BUSINESS ADDRESS:	
		STREET 1:		205 EAST WASHINGTON STREET
		STREET 2:		SUITE B
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(650) 516-7633

	MAIL ADDRESS:	
		STREET 1:		205 EAST WASHINGTON STREET
		STREET 2:		SUITE B
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amesite Operating Co
		DATE OF NAME CHANGE:	20200318
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>ea0289733-s1_amesite.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on May 12, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>THE SECURITIES ACT
OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>AMESITE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7372</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>82-3431717</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</P></TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>607 Shelby Street, Suite 700 PMB 214</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Detroit, MI 48226</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>(734) 876-8141</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Address, including zip
code and telephone number, including area code of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Anne Marie Sastry,
Ph.D.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Amesite Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>607 Shelby Street, Suite 700 PMB 214</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Detroit, MI 48226</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>(734) 876-8141</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Name, address, including
zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Richard A. Friedman, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Sean F. Reid, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Sheppard, Mullin, Richter &amp; Hampton LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>30 Rockefeller Plaza</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B> <B>New York, NY 10112-0015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B> <B>Tel.: (212) 653-8700</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Approximate date of
commencement of proposed sale to the public:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>As soon as practicable
after the date this registration statement becomes effective.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box: &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933, or until the Registration Statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="color: Red">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="color: Red">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>DATED
    MAY 12, 2026</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Up to 4,836,245 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;<IMG SRC="ea028973301_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Amesite Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this prospectus, the selling stockholders
identified herein (the &ldquo;Selling Stockholders&rdquo;) are offering on a resale basis an aggregate of 4,836,245 shares of common stock,
par value $0.0001 per share (the &ldquo;Common Stock&rdquo;) of Amesite Inc. (the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
or &ldquo;our&rdquo;) consisting of (i) 418,118 shares of Common Stock issued pursuant to a securities purchase agreement entered into
by and between us and the Selling Stockholders dated April 27, 2026 (the &ldquo;Purchase Agreement&rdquo;), (ii) up to 696,866 shares
of Common Stock issuable upon exercise of pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;) issued pursuant to the Purchase
Agreement, (iii) up to 1,811,850 shares of Common Stock issuable upon exercise of Series A-1 warrants (the &ldquo;Series A-1 Warrants&rdquo;)
issued pursuant to the Purchase Agreement, (iv) up to 1,811,850 shares of Common Stock issuable upon exercise of Series A-2 warrants (the
&ldquo;Series A-2 Warrants&rdquo;) issued pursuant to the Purchase Agreement, and (v) up to 97,561 shares of Common Stock issuable upon
exercise of warrants (the &ldquo;Placement Agent Warrants) issued pursuant to the engagement agreement dated as of April 26, 2026, by
and between the Company and H.C. Wainwright &amp; Co., LLC (the &ldquo;Placement Agent&rdquo;) The Pre-Funded Warrants, Series A-1 Warrants,
Series A-2 Warrants and Placement Agent Warrants are collectively referred to herein as the &ldquo;Warrants&rdquo;.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any of the proceeds from the
sale by the Selling Stockholders of the Common Stock. Upon any exercise of the Warrants by payment of cash, however, we will receive the
exercise price of the Warrants, which, if exercised in cash with respect to the 4,836,245 shares of Common Stock offered hereby, would
result in gross proceeds to us of approximately $5.38 million. However, we cannot predict when and in what amounts or if the Warrants
will be exercised by payments of cash and it is possible that the Warrants may expire and never be exercised, in which case we would not
receive any cash proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may sell or otherwise
dispose of the Common Stock covered by this prospectus in a number of different ways and at varying prices. We provide more information
about how the Selling Stockholders may sell or otherwise dispose of the Common Stock covered by this prospectus in the section entitled
&ldquo;Plan of Distribution&rdquo; on page 32. Discounts, concessions, commissions and similar selling expenses attributable to the sale
of Common Stock covered by this prospectus, if any, will be borne by the Selling Stockholders. We will pay all expenses (other than discounts,
concessions, commissions and similar selling expenses) relating to the registration of the Common Stock with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on The Nasdaq Capital
Market under the symbol &ldquo;AMST&rdquo;. <FONT STYLE="background-color: white">There is no established trading market for the Warrants
and we do not intend to list the Warrants on any securities exchange or nationally recognized trading system. On May 1, 2026, the last
reported sales price of our common stock was $1.05 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public
company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, together with
the additional information described under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of
Documents by Reference,&rdquo; carefully before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock is highly
speculative and involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 5 of this prospectus for a
discussion of information that should be considered in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION REGARDING FORWARD-LOOKING
    STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DETERMINATION OF THE OFFERING
    PRICE</FONT></A></TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL
    STOCK</FONT></A></TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE
    INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF DOCUMENTS
    BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center">35</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale by the Selling
Stockholders identified in this prospectus under the caption &ldquo;Selling Stockholders,&rdquo; from time to time, of up to an aggregate
of 4,836,245 shares of Common Stock. We are not selling any shares of Common Stock under this prospectus, and we will not receive any
proceeds from the sale of shares of Common Stock offered hereby by the Selling Stockholders, although we may receive cash from the exercise
of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information provided
in this prospectus, including any information incorporated by reference. We have not authorized anyone to provide you with any other information
and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give
you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent
changes in our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not, and the Selling Stockholders are not,
making offers to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which
the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or
solicitation. You should read this prospectus, including any information incorporated by reference, in its entirety before making an investment
decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) that involve risks and uncertainties. You should not place undue reliance
on these forward-looking statements. All statements other than statements of historical facts contained in this prospectus are forward-looking
statements. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely
on our current expectations and projections about future events and financial trends that we believe may affect our business, financial
condition, and results of operations. In some cases, you can identify these forward-looking statements by terms such as &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;depends,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expects,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms or other similar expressions, although not
all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections
about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term
business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements
concerning the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amesite, Inc.&rsquo;s suite of assets is collectively
referred to as our &ldquo;Site.&rdquo; Our Site includes all of our products and services and all of the technology and business services
that create them, in part or whole: a blend of software, hardware, content, and technology that includes everything from behind-the-scenes
processes to the user interface, our website, data handling, communication, and advanced analytics. The NurseMagic&trade; website available
at https://www.nursemagic.ai, and/or our mobile app available at https://app.nursemagic.ai, NurseMagic&trade; is a product owned and operated
by Amesite, Inc. (&ldquo;Amesite,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of risks related to
our Site:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our planned expansions and improvements to our Site, and our ability to deliver solutions that demonstrably offer meaningful return on investment (ROI) to our customers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to deliver our Site to our customers at a price point that enables us to generate sufficient revenue to become profitable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue as a going concern;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need to raise substantial additional capital to fund our operations;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain intellectual property protection for our technologies and our ability to operate our business without infringing the intellectual property rights of others;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on third parties to conduct our business and studies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract and retain qualified key management and technical personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or JOBS Act;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our financial performance;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of government regulation and developments relating to our competitors or our industry; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks and uncertainties, including those listed under the caption &ldquo;Risk Factors.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are subject to
a number of risks, uncertainties and assumptions, including those described in &ldquo;Risk Factors.&rdquo; Moreover, we operate in a very
competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all
risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties
and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ
materially and adversely from those anticipated or implied in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not rely upon forward-looking statements
as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking
statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for
the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements
for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus and the documents
that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is
a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially
different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary highlights selected information
contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included
elsewhere in this prospectus and the information incorporated by reference herein. It does not contain all the information that may be
important to you and your investment decision. You should carefully read this entire prospectus, including the matters set forth under
&ldquo;Risk Factors,&rdquo; and our financial statements and related notes included elsewhere in this prospectus and incorporated by reference
herein. In this prospectus, unless context requires otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Amesite,&rdquo;
or &ldquo;the Company&rdquo; refer to Amesite Inc., a Delaware corporation, and its subsidiaries, unless the context otherwise requires.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Amesite is a technology
company focused on building and commercializing AI-powered solutions for the healthcare sector, with particular emphasis on the post-acute
care market. In fiscal 2025, we completed our pivot from an education-centric model to one firmly anchored in the demands and opportunities
of healthcare&mdash;a shift driven by the scale, complexity, and attractive growth potential of this sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We operate through two
product lines under our NurseMagic&trade; brand: a B2C (direct-to-practitioner) app and a B2B (enterprise) platform. These solutions directly
address operational, compliance, and efficiency challenges faced by healthcare professionals and organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our B2C NurseMagic&trade;
app connects directly with working nurses and caregivers, providing tools to reduce documentation time, simplify communication, and support
daily workflow. Feedback and usage patterns from these users have been instrumental, allowing us to rapidly refine features and ensure
our offerings are relevant to current industry demands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Building on these real-world
insights, our B2B NurseMagic&trade; solution serves healthcare businesses&mdash;including home health, skilled nursing, hospice, and non-clinical
segments. Enterprises adopting NurseMagic&trade; see improvements in workflow efficiency, data security, and regulatory compliance, all
foundational to driving sustainable business performance. Our offerings are engineered for fast, secure deployment and measurable value
in demanding business environments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe that we have
a pathway to deliver AI solutions impactfully, quickly, and compliantly across this expansive, underserved segment. Adoption by both caregivers
and enterprise partners demonstrates the relevance and commercial fit of our technology. Growth in contracted organizations and end users,
alongside positive market feedback, provides further confidence in the direction we have chosen&mdash;even as we remain measured and pragmatic
about future expansion. Significant risks remain for us in the space as we navigate customer, regulatory and user requirements, while
continuing to strive to offer innovative solutions. We face substantial competition from existing players, who have already overcome these
hurdles. Though we are committed to delivering innovation to a space that we believe is hungry for it, we will also have the additional
work of convincing customers to choose our technology-driven approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our Amesite Engage platform,
meanwhile, remains a performant solution for its user base, though we are not dedicating resources to its growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Overall, we believe that
we have consistently endeavored to provide strong fiscal discipline, launching and scaling innovative products while managing costs and
prioritizing efficient resource allocation. We believe this disciplined approach strengthens our potential to grow responsibly, and ultimately,
profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Our Sales and Marketing
Motions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Amesite&rsquo;s go-to-market
strategy for NurseMagic&trade; is distinctly structured for B2C and B2B audiences, leveraging our growing insights from both segments
to build market share, drive recurring revenue, and establish the brand as a trusted, high-value solution for all individual nurses, and
for businesses in post-acute care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>B2C Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For individual nurses
and caregivers, we offer a free version of NurseMagic&trade;. This approach lowers barriers to adoption and enables us to gather invaluable,
real-world feedback quickly, helping us refine features, tailor language, and build a user community that advocates for the product. Our
B2C marketing utilizes digital outreach, targeted social media campaigns and community engagement to increase awareness and credibility.
The app&rsquo;s everyday utility and ease-of-use are promoted through user testimonials, while customer support and product updates sustain
positive reviews and word-of-mouth growth. Widespread adoption among practitioners enhances our reputation and provides invaluable reference
points as we approach enterprise buyers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>B2B Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our B2B sales effort
targets healthcare enterprises operating in post-acute settings, spanning home health, skilled nursing, hospice, assisted and senior living
centers. Our sales motion is outcome-focused: we identify organizations facing acute staffing and operational pain, then directly connect
with decision-makers. Our B2C solution offers a free version, enabling decision-makers to test the app and quickly validate impact and
reduce hesitancy. We emphasize NurseMagic&trade;&rsquo;s potential to save time, support regulatory compliance, enhance documentation
accuracy, and drive measurable improvements in staff efficiency and retention. We strive to deploy rapidly, ensuring business continuity
and value realization. Feedback from both administrators and frontline staff informs product development and strengthens our relationships
with enterprise customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our disciplined, evidence-based
approach in both segments supports Amesite&rsquo;s reputation as a partner that delivers real solutions to pressing business challenges,
helping drive strong adoption, build reference customers, and sustain healthy growth, even in complex, compliance-intensive markets. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Our Technology and
Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Amesite&rsquo;s technology
platform is purpose-built to rapidly deliver high-impact, compliant solutions across healthcare and corporate learning. We power both
our NurseMagic&trade; and Amesite Engage products from a coordinated infrastructure built for security, flexibility, and speed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our core architecture
uses modern, best-in-class languages and frameworks for both client and server-side development, supporting robust, scalable front-end
tools. This design gives our engineering team exceptional agility, simplifying the integration of new functionalities and APIs as soon
as they become available. By leveraging both widely adopted technologies and proprietary models, trained on selectively curated datasets,
we aim to deliver meaningful, real-world improvements for our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Notable milestones include
the commercialization of NurseMagic&trade; for both B2C and B2B users, the rollout of HIPAA-compliant enterprise workflows, and deployment
of features specifically requested by frontline healthcare professionals. We also invested in our data infrastructure, ensuring continual
performance improvement while maintaining data security and compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We collect information
on user behavior and product use, only with full user consent, to drive product enhancements. Our data practices prioritize security,
confidentiality, and compliance with evolving regulations, especially relevant in complex healthcare contexts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Agility is a central
goal of our R&amp;D culture. Our team, benefiting from decades of collective experience in technology, endeavors to deliver continuous
improvement against stringent, best-in-class metrics. We launch more than five new features and capabilities per week, prioritizing those
that solve urgent user problems and are directly usable by our customers. All R&amp;D resources are squarely dedicated to delivering tangible
improvements in user experience and operational impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our deployments are designed
for simplicity and scale: NurseMagic&trade; aims to be fully deployable to every type of employee in an enterprise, requiring no external
system integration, and is administered entirely within the app. Feature sets are intended to be configurable to individual customer needs,
allowing organizations to adapt our solution to their workflows and rapidly realize value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our relentless focus
on innovation, speed, and user impact underpins Amesite&rsquo;s mission to stay ahead of the curve, helping drive customer satisfaction,
adoption, and business performance across rapidly evolving market segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, and our telephone number is (734) 876-8130. Our website address is <I>www.amesite.com</I>.
The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information
contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.235 billion in
revenues during our last fiscal year, we qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act (&ldquo;JOBS
Act&rdquo;) enacted in 2012. As an emerging growth company, we expect to take advantage of reduced reporting requirements that are otherwise
applicable to public companies. These provisions include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; disclosure in this prospectus;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&ldquo;Sarbanes-Oxley Act&rdquo;);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may use these provisions until the last day
of our fiscal year following the fifth anniversary of the completion of our initial public offering. However, if certain events occur
prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our annual gross revenues exceed
$1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth
company prior to the end of such five-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. As an emerging growth
company, we intend to take advantage of an extended transition period for complying with new or revised accounting standards as permitted
by The JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock being Offered</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 64%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 4,836,245 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of shares of common stock outstanding prior to this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,434,867 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of shares of common stock to be outstanding after this offering (1)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,271,112, assuming the exercise of all of the Warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 64%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not
    receive any proceeds from the sale of the shares of Common Stock by the Selling Stockholders, except for the warrant exercise price
    paid for the Common Stock offered hereby and issuable upon the exercise of the Warrants.&nbsp;See &ldquo;Use of Proceeds&rdquo; on
    page 16 of this prospectus.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our common stock involves a high degree of risk. See &ldquo;Risk
Factors&rdquo; beginning on page 5 of this prospectus, and &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended
June 30, 2025, and our Quarterly Reports on Form 10-Q for the quarters ended September 30, 2025, and December 31, 2025, each as incorporated
by reference into this prospectus, for a discussion of factors to consider prior to deciding to invest in our common stock, or warrants
that will accompany such securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq Capital Market Symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;AMST&rdquo;.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established trading market for the
    Warrants, and we do not expect a trading market to develop. We do not intend to list the Warrants on any securities exchange or nationally
    recognized trading system.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The number of shares of our common stock to be outstanding
after this offering is based on 5,434,867 shares of our common stock outstanding as of May 1, 2026, and excludes:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166,352 shares of common stock issuable upon exercise of outstanding options with a weighted average exercise price of $22.26; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416,561 shares of common stock issuable upon exercise of outstanding warrants with a weighted average exercise price of $9.20.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>An investment in our securities involves a
high degree of risk. Prior to making a decision about investing in our securities, you should carefully consider the risk factors described
below and the risk factors discussed in the sections entitled &ldquo;Risk Factors&rdquo; contained in our most recent Annual Report on
Form 10-K, as amended, and Quarterly Report on Form 10-Q, as may be amended, supplemented or superseded from time to time by other reports
we file with the SEC and incorporated by reference in this prospectus, together with all of the other information contained in this prospectus.
Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If
any of the risks or uncertainties described in our SEC filings or this prospectus or any additional risks and uncertainties actually occur,
our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price
of our common stock could decline and you might lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Healthcare and AI Solutions
Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compliance and Regulatory Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our NurseMagic&trade; solution is designed for
use across post-acute healthcare settings, including skilled nursing, assisted living, memory care, home health, and rehabilitation. The
healthcare sector is highly regulated on both federal and state levels, particularly with respect to patient privacy, data security, and
the integrity of AI-driven tools. Any failure&mdash;by us or our customers&mdash;to maintain compliance with applicable laws such as HIPAA,
the HITECH Act, CMS rules, and emerging AI-focused regulations (including transparency, bias, and cybersecurity standards) could expose
us to significant penalties, legal action, or restrictions on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also required to address evolving and overlapping
data privacy laws at the state, national, and international levels (such as GDPR). Compliance complexity may increase as AI regulations
continue to be introduced and interpreted, and any compliance lapse by us, our customers, or our partners could result in fines, reputational
harm, or loss of customer trust.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Adoption, Market Penetration, and Growth Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The healthcare software industry is intensely
competitive, with established platforms, agile mid-market firms, and numerous AI-first entrants, many of whom have more resources and
larger installed bases. While NurseMagic&trade; is designed for easy onboarding and rapid deployment, there is no guarantee that healthcare
organizations and individual practitioners will continue to adopt our platform, perceive sufficient differentiation or ROI, or retain
their subscriptions over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future performance depends on continued growth
in the post-acute care market, successful marketing and sales execution, our ability to respond to changing customer needs, and the overall
pace of adoption of AI-powered solutions in healthcare. Market acceptance could be impeded by factors including organizational inertia,
integration challenges, the emergence of competing technologies, or negative perceptions of AI in clinical environments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Technology, Data, and Operational Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an AI-driven SaaS provider, we rely on the
robustness, accuracy, and security of our proprietary technologies for documentation, workflow automation, and compliance. Bugs, performance
issues, or unexpected behavior in our algorithms could disrupt customer operations, erode trust, or expose sensitive data. The rapid pace
of AI innovation requires ongoing investment in research, data infrastructure, and security practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face persistent cybersecurity and data protection
risks inherent in managing health-related and personal information. Any breach, unauthorized access, or misuse could have severe financial,
reputational, and legal consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financial and Business Model Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not yet established a stable, recurring
revenue base sufficient to cover ongoing expenses, and we have incurred net losses in recent fiscal years. If we fail to achieve broad
adoption, maintain or grow our customer base, or realize operational efficiencies, we could be forced to scale back investment, which
would limit future opportunities and weaken our competitive position. As a public company, we must also bear considerable administrative,
accounting, and compliance expenses regardless of operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General and Macroeconomic Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General economic downturns, reductions in healthcare
or IT spending, changes in regulatory or reimbursement environments, or disruptions to our own workforce or supply chain could adversely
impact sales, revenue, or execution capacity. Our continued viability as a going concern depends on addressing these risks and achieving
sufficient and sustained commercial momentum in our core markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In summary, our success depends on our ability
to continuously adapt to regulatory change, maintain differentiation and trust in an evolving AI landscape, and execute our operational
and financial plan in the face of robust industry competition and macro-level uncertainties. Failure to manage these risks could materially
and adversely affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face significant operational and financial
risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Implementing and maintaining NurseMagic&trade;
across diverse healthcare environments poses significant operational challenges. Each modality has unique requirements and workflows,
and the app must be highly adaptable to meet these needs. The cost and complexity of developing features tailored to specific healthcare
settings, as well as ensuring robust data security and performance, require substantial investment. If we are unable to effectively allocate
resources to these areas, our growth and operational stability could be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we incur significant overhead
costs related to compliance, accounting, and legal obligations. If NurseMagic&trade; does not achieve the expected revenue or market penetration,
we may be forced to scale back development and marketing efforts, which could hinder our ability to attract new customers and retain existing
ones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face combined legal and reputational
risks because of the data we manage and the nature of the business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to meet regulatory standards or to ensure
the app&rsquo;s reliability and security could result in negative publicity, loss of trust, and damage to our brand reputation. This could
lead to decreased user engagement and lower conversion rates for enterprise licenses. Additionally, any legal actions taken against us
for non-compliance, data breaches, or misuse of the app could result in significant financial penalties and long-term damage to our business
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In summary, the success of NurseMagic&trade; depends
on our ability to navigate complex regulatory landscapes, effectively differentiate ourselves in a competitive market, and maintain operational
and financial stability. Failure to manage these risks could materially and adversely affect our business, financial condition, and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is substantial doubt about our ability
to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are in the early stages of developing our customer
base and have not completed our efforts to establish a stabilized source of revenue sufficient to cover our costs over an extended period
of time. For the years ended June 30, 2025 and 2024, we had net losses of approximately $3,617,000 and $4,403,000, respectively. The assessment
of the Company&rsquo;s ability to meet its future obligations is inherently judgmental, subjective and susceptible to change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on their current forecast, management believes
that it may not have sufficient cash and cash equivalents to maintain the Company&rsquo;s planned operations for the next twelve months
following the issuance of these financial statements. The Company has considered both quantitative and qualitative factors that are known
or reasonably known as of the date of these financial statements are issued and concluded that there are conditions present in the aggregate
that raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In response to the conditions, management plans
include generating cash by completing financing transactions, which may include offerings of common stock. However, these plans are subject
to market conditions, and are not within the Company&rsquo;s control, and therefore, cannot be deemed probable. There is no assurance
that the Company will be successful in implementing their plans. As a result, the Company has concluded that management&rsquo;s plans
do not alleviate substantial doubt about the Company&rsquo;s ability to continue as a going concern. The financial statements do not include
any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities
that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on the services of certain
key management personnel, employees, advisors, and consultants. If we are unable to retain or motivate such individuals or hire qualified
personnel, we may not be able to grow effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate leanly, but as such we depend on the
services of a number of key management personnel, employees, advisors and consultants and our future performance will largely depend on
the talents and efforts of such individuals. We do not currently maintain &ldquo;key person&rdquo; life insurance on any of our employees,
except for our Chief Executive Officer. The loss of one or more of such key individuals, or failure to find a suitable successor, could
hamper our efforts to successfully operate our business and achieve our business objectives. Our future success will also depend on our
ability to identify, hire, develop, motivate and retain highly skilled personnel. Competition in our industry for qualified employees
is intense, and our compensation arrangements may not always be successful in attracting new employees and/or retaining and motivating
our existing employees. Future acquisitions by us may also cause uncertainty among our current employees and employees of the acquired
entity, which could lead to the departure of key individuals. Such departures could have an adverse impact on the anticipated benefits
of an acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have risk factors within and outside
of our control that may inhibit our ability to deliver products on our platform.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our customers will rely on us to deliver stable
platforms, with correct measures of performance in a manner that users can easily use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating results are highly susceptible to
fluctuations due to numerous factors, many of which are beyond our control. We may be unable to compete effectively in the marketplace,
which could hinder our ability to attract and retain users and customers on our platform. The mix of net revenues generated from different
customer segments may not align with our expectations, leading to unpredictable financial outcomes. Additionally, the timing and magnitude
of operating costs and capital expenditures required to maintain and expand our business, operations, and infrastructure may exceed our
forecasts, adversely impacting our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our focus on long-term objectives over immediate
financial performance could result in periods of suboptimal results, and our investments in high-risk projects may fail to generate anticipated
returns. Adverse economic conditions, both broadly and specific to our industry, could further weaken our financial position. We may struggle
to keep our platform operational at a reasonable cost or without service interruptions, which could damage our reputation and erode user
trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our geographical and product expansion initiatives
may not achieve the intended outcomes, and we may fail to attract, inspire, and retain top-tier talent, impeding our ability to succeed
at any scale. Government regulations-whether foreign, federal, state, or local-could impose constraints on our operations, potentially
limiting our growth. We may be unable to effectively upgrade and develop our systems, infrastructure, and products, or to address emerging
technologies or services that block our platform, leading to reduced user engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We could face substantial costs and uncertainties
from litigation, and we may not be able to protect our intellectual property rights, which could erode our competitive position. Our revenue
forecasting may be inaccurate, leading to misguided strategic decisions. Additionally, we may fail to manage fraud and other activities
that violate our terms of service, further compromising our platform&rsquo;s integrity. Our ability to successfully integrate and manage
our relationships with enterprises in healthcare and with colleges and universities is uncertain, and any failure in either segment could
diminish our reputation. Finally, geopolitical events such as war, threats of war, or terrorist actions could disrupt our operations and
significantly impair our business performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may have risks related to our financial
condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a history of losses, will need substantial
additional funding to continue our operations and may not achieve or sustain profitability in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations have consumed substantial amounts
of cash since inception. If our expectations prove incorrect, our business, operating results and financial condition will be materially
and adversely affected. We anticipate that our operating expenses may increase in the foreseeable future as we continue to pursue the
development of our platform, invest in marketing, sales and distribution of our platform to grow our business, acquire customers, and
commercialize our technology. These efforts may prove more expensive than we currently anticipate, and we may not succeed in generating
sufficient revenues to offset these increased expenses. In addition, we expect to incur significant expenses related to regulatory requirements,
and our ability to obtain, protect, and defend our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also encounter unforeseen expenses, difficulties,
complications, delays, and other unknown factors that may increase our capital needs and/or cause us to spend our cash resources faster
than we expect. Accordingly, we may need to obtain substantial additional funding to continue our operations. We cannot assure you that
such additional funding will be available on favorable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may have risks related to managing any
growth we may experience.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may engage in future acquisitions that could
disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While there are currently no specific plans to
acquire any other businesses, we may, in the future, make acquisitions of, or investments in, companies that we believe have products
or capabilities that are a strategic or commercial fit with our current business or otherwise offer opportunities. In connection with
these acquisitions or investments, we may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares of our common stock or other forms of equity that would dilute our existing stockholders&rsquo; percentage of ownership;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur debt and assume liabilities; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to complete acquisitions on
favorable terms, if at all. If we do complete an acquisition, we cannot assure you that such acquisition will ultimately strengthen our
competitive position or that such acquisition will be viewed positively by customers, financial markets, or investors. Furthermore, future
acquisitions could pose numerous additional risks to our expected operations, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">problems integrating the purchased business, products, or technologies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges in achieving strategic objectives, cost savings and other anticipated benefits;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases to our expenses;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of significant liabilities that exceed the limitations of any applicable indemnification provisions or the financial resources of any indemnifying party;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to maintain relationships with prospective key customers, vendors, and other business partners of the acquired businesses;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management&rsquo;s attention from their day-to-day responsibilities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty in maintaining controls, procedures and policies during the transition and integration;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entrance into marketplaces where we have limited or no prior experience and where competitors have stronger marketplace positions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential loss of key employees, particularly those of the acquired entity;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that historical financial information may not be representative or indicative of results as a combined entity; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that our business and operations would suffer in the event of system failures, and our operations are vulnerable to interruption by natural disasters, terrorist activity, power loss and other events beyond our control, the occurrence of which could materially harm our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our security measures or those of our
future business partners are breached or fail and result in unauthorized disclosure of data, we could lose customers and/or fail to attract
new customers. Such breach or failure could also harm our reputation and expose us to protracted and costly lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our platform and computer systems store and transmit
proprietary and confidential information that is subject to stringent legal and regulatory obligations. Due to the nature of our products,
we face an increasing number of threats to our platform and computer systems including unauthorized activity and access, system viruses,
worms, malicious code, denial of service attacks, and organized cyberattacks, any of which could breach our security and disrupt our platform.
The techniques used by computer hackers and cyber criminals to obtain unauthorized access to data or to sabotage computer systems change
frequently and generally are not detected until after an incident has occurred. Our cybersecurity measures or those of our future business
partners may be unable to anticipate, detect or prevent all attempts to compromise our systems or those of our future business partners.
Our internal computer systems and those of our future business partners are or may also be vulnerable to telecommunication and electrical
failures, the occurrence of which could result in material disruptions of our services. If our security measures are breached or fail
because of third-party action, employee error, malfeasance or otherwise, we could be subject to liability or our business could be interrupted,
potentially over an extended period of time. Any or all of these issues could harm our reputation, adversely affect our ability to attract
new customers, cause existing customers to scale back their offerings or elect not to renew their agreements, cause prospective students
not to enroll or students to not stay enrolled in our offerings, or subject us to third-party lawsuits, regulatory fines or other action
or liability. Such issues could also cause a delay in the further development of our new technology for online education. Any reputational
damage resulting from breach of our systems or disruption of our services could create distrust of our company by prospective customers.
We do not currently have cyber risk insurance. If we obtain one, such insurance may not be adequate to cover losses associated with such
events, and in any case, such insurance may not cover all of the types of costs, expenses and losses we could incur to respond to and
remediate a security breach. As a result, we may be required to expend significant additional resources to protect against the threat
of these disruptions and security breaches or to alleviate problems caused by such disruptions or breaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unfavorable global economic, business, or
political conditions could adversely affect our business, financial condition or results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations could be adversely affected
by general conditions in the global economy and in the global financial markets, including conditions that are outside of our control
and the impact of health and safety concerns. A severe or prolonged economic downturn caused by this or other general conditions could
result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at
all. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current economic climate and financial
market conditions could adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cyber security risks and the failure to
maintain the integrity of internal, partner, and consumer data could result in damages to our reputation, the disruption of operations
and/or subject us to costs, fines or lawsuits.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have and will continue to collect and retain
large volumes of internal, user and customer data, including personally identifiable information, for business purposes, including for
transactional or target marketing and promotional purposes, and our various information technology systems enter, process, summarize and
report such data. We also maintain personally identifiable information about our employees. The integrity and protection of our customer,
employee, and Company data is critical to our business and our customers and employees are likely to have a high expectation that we will
adequately protect their personal information. The regulatory environment, as well as the requirements imposed on us by the credit card
industry, governing information, security and privacy laws is increasingly demanding and continues to evolve. Maintaining compliance with
applicable security and privacy regulations may increase our operating costs and/or adversely impact our ability to market our products
and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on accounting, financial and operational
management information technology systems to conduct our operations. If these information technology systems suffer severe damage, disruption
or shutdown and our business continuity plans do not effectively resolve the issues in a timely manner, our business, financial condition
and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may face various security threats, including
cyber security attacks on our data (including our vendors&rsquo; and customers&rsquo; data) and/or information technology infrastructure.
Although we utilize various procedures and controls to monitor and mitigate these threats, there can be no assurance that these procedures
and controls will be sufficient to prevent penetrations or disruptions to our systems. Furthermore, a penetrated or compromised data system
or the intentional, inadvertent or negligent release or disclosure of data could result in theft, loss, fraudulent or unlawful use of
customer, employee, or Company data which could harm our reputation or result in remedial and other costs, fines or lawsuits and require
significant management attention and resources to be spent. In addition, our insurance coverage and indemnification arrangements that
we enter into, if any, may not be adequate to cover all the costs related to cyber security attacks or disruptions resulting from such
events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>An active trading market for our common
stock may not be sustained.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although our common stock is listed on the Nasdaq
Capital Market, the market for our shares has demonstrated varying levels of trading activity. Furthermore, the current level of trading
may not be sustained in the future. The lack of an active market for our common stock may impair investors&rsquo; ability to sell their
shares at the time they wish to sell them or at a price that they consider reasonable, may reduce the fair market value of their shares
and may impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire additional
intellectual property assets by using our shares as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may acquire other companies or technologies,
which could divert our management&rsquo;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely
affect our operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may in the future seek to acquire or invest
in businesses, applications and services or technologies that we believe could complement or expand our services, enhance our technical
capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and
cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we do not have any experience in
acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and
technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated
benefits from the acquired business due to several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to integrate or benefit from acquired technologies or services in a profitable manner;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated costs or liabilities associated with the acquisition;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty integrating the accounting systems, operations and personnel of the acquired business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty converting the customers of the acquired business onto our platform and contract terms, including disparities in the revenue, licensing, support or professional services model of the acquired company;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management&rsquo;s attention from other business concerns;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse effects to our existing business relationships with business partners and customers because of the acquisition;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential loss of key employees;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use of resources that are needed in other parts of our business; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use of substantial portions of our available cash to consummate the acquisition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a significant portion of the purchase
price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment
at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating
results based on this impairment assessment process, which could adversely affect our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions could also result in dilutive issuances
of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business
fails to meet our expectations, our operating results, business and financial position may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Market and economic conditions may negatively
impact our business, financial condition and share price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concerns over inflation, energy costs, geopolitical
issues, the U.S. mortgage market and a declining real estate market, unstable global credit markets and financial conditions, and volatile
oil prices have led to periods of significant economic instability, diminished liquidity and credit availability, declines in consumer
confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth
going forward, increased unemployment rates, and increased credit defaults in recent years. Our general business strategy may be adversely
affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions.
If these conditions continue to deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete,
more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material
adverse effect on our growth strategy, financial performance, and share price and could require us to delay or abandon development or
commercialization plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales and issuances of our securities
could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that significant additional capital
will be needed in the future to continue our planned operations, including research and development, increased marketing, hiring new personnel,
commercializing our products, and continuing activities as an operating public company. To the extent we raise additional capital by issuing
equity securities, our shareholders may experience substantial dilution. We may sell common stock, convertible securities or other equity
securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible
securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales
may also result in material dilution to our existing shareholders, and new investors could gain rights superior to our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay cash dividends on
our shares of common stock so any returns will be limited to the value of our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently anticipate that we will retain future
earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for
the foreseeable future. Any return to shareholders will therefore be limited to the increase, if any, of our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth company&rdquo;
and can avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock
less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;), and we have elected to take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved. In addition, pursuant to Section 107 of the JOBS Act, as an &ldquo;emerging growth company&rdquo; we have elected to take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards.
In other words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. As such, our financial statements may not be comparable to companies that comply with public
company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be at risk of securities class action
litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be at risk of securities class action litigation.
In the past, small-cap issuers have experienced significant stock price volatility, particularly when associated with regulatory requirements
by governmental authorities, which our industry now increasingly faces. If we face such litigation, it could result in substantial costs
and a diversion of management&rsquo;s attention and resources, which could harm our business and result in a decline in the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>If we are unable
to comply with the continued listing requirements of the Nasdaq Capital Market, then our common stock would be delisted from the Nasdaq
Capital Market, which would limit investors&rsquo; ability to effect transactions in our common stock and subject us to additional trading
restrictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 28, 2025 we
received a deficiency letter (the &ldquo;Nasdaq Letter&rdquo;) from the Listing Qualifications Department of The Nasdaq Stock Market LLC
(&ldquo;Nasdaq&rdquo;) notifying us that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires us to maintain
a minimum of $2,500,000 in stockholders&rsquo; equity for continued listing on the Nasdaq Capital Market (the &ldquo;Stockholders&rsquo;
Equity Requirement&rdquo;), nor were we in compliance with either of the alternative listing standards, either a market value of listed
securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or
in two of the three most recently completed fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the Nasdaq
Letter, we had 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance. We submitted our plan of compliance
on December 10, 2025 and on January 8, 2026, Nasdaq granted an extension until April 27, 2026 to evidence compliance. Upon completion
of the private placement transactions under the Purchase Agreement as well as the registered direct offering that we completed concurrently
therewith, we believe that our stockholders&rsquo; equity <FONT STYLE="background-color: white">will be in excess of $2.5 million necessary
to regain compliance with Nasdaq&rsquo;s minimum stockholder&rsquo; equity requirement. It is expected that Nasdaq will continue to monitor
our ongoing compliance with the stockholders&rsquo; equity requirement and, if at the time of its next periodic report we do not evidence
compliance, we may be subject to delisting. We are is awaiting Nasdaq&rsquo;s determination that it has regained compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We intend to take all
reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be
no assurance that we will be successful in maintaining compliance with the Stockholders&rsquo; Equity Requirement and all applicable requirements
for continued listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Neither the Nasdaq Letter
nor our noncompliance have an immediate effect on the listing or trading of our common shares, which will continue to trade on the Nasdaq
Capital Market under the symbol &ldquo;AMST.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If the Nasdaq Capital
Market delists our common stock from trading on its exchange and we are not able to list our securities on another national securities
exchange, we expect the common stock would qualify to be quoted on an over-the-counter market. If this were to occur, we could face significant
material adverse consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited availability of market quotations for our securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced liquidity for our securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantially impair our ability to raise additional funds;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the loss of institutional investor interest and a decreased ability to issue additional securities or obtain additional financing in the future;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a determination that our common stock is a &ldquo;penny stock,&rdquo; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited amount of news and analyst coverage; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential breaches of representations or covenants of our agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements, which, regardless of merit, could result in costly litigation, significant liabilities and diversion of our management&rsquo;s time and attention and could have a material adverse effect on our financial condition, business and results of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are required to develop and maintain
proper and effective internal controls over financial reporting. We may not complete our analysis of our internal controls over financial
reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence
in us and, as a result, the value of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required, pursuant to Section 404 of the
Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal controls over financial
reporting for the fiscal year ending June 30, 2025. This assessment will need to include disclosure of any material weaknesses identified
by our management in our internal controls over financial reporting. Additionally, we are required to disclose changes made in our internal
controls and procedures on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, as long as we are an emerging growth
company, or a smaller reporting company that is a non-accelerated filer, our independent registered public accounting firm will not be
required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404(b). At such time this
attestation will be required, our independent registered public accounting firm may issue a report that is adverse in the event the independent
registered public accounting firm concludes that there is one or more material weaknesses in the effectiveness of our internal control
over financial reporting. Our remediation efforts may not enable us to avoid a material weakness in the future. We may need to undertake
various actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to assert that our internal controls
over financial reporting are effective, or if our independent registered public accounting firm is unable to express an opinion on the
effectiveness of our internal controls to the extent required, we could lose investor confidence in the accuracy and completeness of our
financial reports, which could cause the price of our common stock to decline, and we may be subject to investigation or sanctions by
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Financial reporting obligations of being
a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time
to compliance matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a publicly traded company, we incur significant
additional legal, accounting, and other expenses that we did not incur as a private company. The obligations of being a public company
in the United States require significant expenditures and will place significant demands on our management and other personnel, including
costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance
practices, including those under the Sarbanes-Oxley Act of 2002 (&ldquo;Sarbanes-Oxley&rdquo;) the Dodd-Frank Wall Street Reform and Consumer
Protection Act, and the listing requirements of the stock exchange on which our securities are listed. These rules require the establishment
and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in
corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance
with. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some
activities more time-consuming and costly, particularly after we are no longer an &ldquo;emerging growth company.&rdquo; Our management
and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with
new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential
problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our principal stockholders and management
own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors, executive officers and each of
our stockholders who owned greater than 5% of our outstanding Common Stock beneficially, as of May 1, 2026, own approximately [23]% of
our common stock. Accordingly, these stockholders have and will continue to have significant influence over the outcome of corporate actions
requiring stockholder approval, including the election of directors, a merger, the consolidation, or sale of all or substantially all
of our assets or any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict
with our other investors&rsquo; interests. For example, these stockholders could delay or prevent a change in control of us, even if such
a change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium
for their Common Stock as part of a sale of the Company or our assets. The significant concentration of stock ownership may negatively
impact the value of our Common Stock due to potential investors&rsquo; perception that conflicts of interest may exist or arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our certificate of incorporation provides
that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between the Company
and its stockholders, which could limit stockholders&rsquo; ability to obtain a favorable judicial forum for disputes with the Company
or its directors, officers, or employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation provides that
unless the Company consents in writing to the selection of an alternative forum, the State of Delaware is the sole and exclusive forum
for: (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary
duty owed by any director, officer or other employee of the Company to the Company or the Company&rsquo;s stockholders, (iii) any action
asserting a claim against the Company, its directors, officers or employees arising pursuant to any provision of the Delaware General
Corporation Law (the &ldquo;DGCL&rdquo;) or our certificate of incorporation or our bylaws, or (iv) any action asserting a claim against
the Company, its directors, officers, employees or agents governed by the internal affairs doctrine, except for, as to each of (i) through
(iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction
of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten
days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery,
or for which the Court of Chancery does not have subject matter jurisdiction. This exclusive forum provision would not apply to suits
brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts
have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates
exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits
brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 22 of the Securities Act creates concurrent
jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder. However, our certificate of incorporation contains a federal forum provision which provides that unless
the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person
or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation are deemed to have notice of and
consented to this provision. The Supreme Court of Delaware has held that this type of exclusive federal forum provision is enforceable.
There may be uncertainty, however, as to whether courts of other jurisdictions would enforce such provision, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These choice of forum provisions may limit a stockholder&rsquo;s
ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or its directors, officers or other
employees, which may discourage such lawsuits against the Company and its directors, officers and other employees. Alternatively, if a
court were to find our choice of forum provisions contained in either our certificate of incorporation or bylaws to be inapplicable or
unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions, which
could harm its business, results of operations, and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain provisions of our certificate of
incorporation and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete,
even if such a transaction were in stockholders&rsquo; interest.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation and the Delaware
General Corporation Law contain certain provisions that may have the effect of making it more difficult or delaying attempts by others
to obtain control of our Company, even when these attempts may be in the best interests of our stockholders. We also are subject to the
anti-takeover provisions of the Delaware General Corporation Law, which prohibits us from engaging in a &ldquo;business combination&rdquo;
with an &ldquo;interested stockholder&rdquo; unless the business combination is approved in a prescribed manner and prohibits the voting
of shares held by persons acquiring certain numbers of shares without obtaining requisite approval. The statutes and our certificate of
incorporation have the effect of making it more difficult to effect a change in control of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any of the proceeds from the
sale by the Selling Stockholders of the Common Stock. Upon any exercise of the Warrants by payment of cash, however, we will receive the
exercise price of the Warrants, which, if exercised in cash with respect to the 4,836,245 shares of Common Stock offered hereby, would
result in gross proceeds to us of approximately $5.38 million. However, we cannot predict when and in what amounts or if the Warrants
will be exercised by payments of cash and it is possible that the Warrants may expire and never be exercised, in which case we would not
receive any cash proceeds.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have never paid cash
dividends on our Common Stock and we do not anticipate paying cash dividends in the foreseeable future, but intend to retain our capital
resources for reinvestment in our business. Any future determination to pay cash dividends on our Common Stock will be at the discretion
of our board of directors and will be dependent upon our financial condition, results of operations, capital requirements and other factors
as the board of directors deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DETERMINATION OF THE OFFERING PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The prices at which the
shares of Common Stock covered by this prospectus may actually be sold will be determined by the prevailing public market price for shares
of our Common Stock or by negotiations between the Selling Stockholders and buyers of our Common Stock in private transactions or as otherwise
described in &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amesite is a technology company focused on building
and commercializing AI-powered solutions for the healthcare sector, with particular emphasis on the post-acute care market. In fiscal
2025, we completed our pivot from an education-centric model to one firmly anchored in the demands and opportunities of healthcare&mdash;a
shift driven by the scale, complexity, and attractive growth potential of this sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate through two product lines under our
NurseMagic&trade; brand: a B2C (direct-to-practitioner) app and a B2B (enterprise) platform. These solutions directly address operational,
compliance, and efficiency challenges faced by healthcare professionals and organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our B2C NurseMagic&trade; app connects directly
with working nurses and caregivers, providing tools to reduce documentation time, simplify communication, and support daily workflow.
Feedback and usage patterns from these users have been instrumental, allowing us to rapidly refine features and ensure our offerings are
relevant to current industry demands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Building on these real-world insights, our B2B
NurseMagic&trade; solution serves healthcare businesses&mdash;including home health, skilled nursing, hospice, and non-clinical segments.
Enterprises adopting NurseMagic&trade; see improvements in workflow efficiency, data security, and regulatory compliance, all foundational
to driving sustainable business performance. Our offerings are engineered for fast, secure deployment and measurable value in demanding
business environments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we have a pathway to deliver AI
solutions impactfully, quickly, and compliantly across this expansive, underserved segment. Adoption by both caregivers and enterprise
partners demonstrates the relevance and commercial fit of our technology. Growth in contracted organizations and end users, alongside
positive market feedback, provides further confidence in the direction we have chosen&mdash;even as we remain measured and pragmatic about
future expansion. Significant risks remain for us in the space as we navigate customer, regulatory and user requirements, while continuing
to strive to offer innovative solutions. We face substantial competition from existing players, who have already overcome these hurdles.
Though we are committed to delivering innovation to a space that we believe is hungry for it, we will also have the additional work of
convincing customers to choose our technology-driven approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Amesite Engage platform, meanwhile, remains
a performant solution for its user base, though we are not dedicating resources to its growth.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall, we believe that we have consistently
endeavored to provide strong fiscal discipline, launching and scaling innovative products while managing costs and prioritizing efficient
resource allocation. We believe this disciplined approach strengthens our potential to grow responsibly, and ultimately, profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Sales and Marketing Motions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amesite&rsquo;s go-to-market strategy for NurseMagic&trade;
is distinctly structured for B2C and B2B audiences, leveraging our growing insights from both segments to build market share, drive recurring
revenue, and establish the brand as a trusted, high-value solution for all individual nurses, and for businesses in post-acute care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>B2C Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For individual nurses and caregivers, we offer
a free version of NurseMagic&trade;. This approach lowers barriers to adoption and enables us to gather invaluable, real-world feedback
quickly, helping us refine features, tailor language, and build a user community that advocates for the product. Our B2C marketing utilizes
digital outreach, targeted social media campaigns and community engagement to increase awareness and credibility. The app&rsquo;s everyday
utility and ease-of-use are promoted through user testimonials, while customer support and product updates sustain positive reviews and
word-of-mouth growth. Widespread adoption among practitioners enhances our reputation and provides invaluable reference points as we approach
enterprise buyers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>B2B Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our B2B sales effort targets healthcare enterprises
operating in post-acute settings, spanning home health, skilled nursing, hospice, assisted and senior living centers. Our sales motion
is outcome-focused: we identify organizations facing acute staffing and operational pain, then directly connect with decision-makers.
Our B2C solution offers a free version, enabling decision-makers to test the app and quickly validate impact and reduce hesitancy. We
emphasize NurseMagic&trade;&rsquo;s potential to save time, support regulatory compliance, enhance documentation accuracy, and drive measurable
improvements in staff efficiency and retention. We strive to deploy rapidly, ensuring business continuity and value realization. Feedback
from both administrators and frontline staff informs product development and strengthens our relationships with enterprise customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our disciplined, evidence-based approach in both
segments supports Amesite&rsquo;s reputation as a partner that delivers real solutions to pressing business challenges, helping drive
strong adoption, build reference customers, and sustain healthy growth, even in complex, compliance-intensive markets. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Technology and Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amesite&rsquo;s technology platform is purpose-built
to rapidly deliver high-impact, compliant solutions across healthcare and corporate learning. We power both our NurseMagic&trade; and
Amesite Engage products from a coordinated infrastructure built for security, flexibility, and speed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our core architecture uses modern, best-in-class
languages and frameworks for both client and server-side development, supporting robust, scalable front-end tools. This design gives our
engineering team exceptional agility, simplifying the integration of new functionalities and APIs as soon as they become available. By
leveraging both widely adopted technologies and proprietary models, trained on selectively curated datasets, we aim to deliver meaningful,
real-world improvements for our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notable milestones include the commercialization
of NurseMagic&trade; for both B2C and B2B users, the rollout of HIPAA-compliant enterprise workflows, and deployment of features specifically
requested by frontline healthcare professionals. We also invested in our data infrastructure, ensuring continual performance improvement
while maintaining data security and compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We collect information on user behavior and product
use, only with full user consent, to drive product enhancements. Our data practices prioritize security, confidentiality, and compliance
with evolving regulations, especially relevant in complex healthcare contexts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agility is a central goal of our R&amp;D culture.
Our team, benefiting from decades of collective experience in technology, endeavors to deliver continuous improvement against stringent,
best-in-class metrics. We launch more than five new features and capabilities per week, prioritizing those that solve urgent user problems
and are directly usable by our customers. All R&amp;D resources are squarely dedicated to delivering tangible improvements in user experience
and operational impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our deployments are designed for simplicity and
scale: NurseMagic&trade; aims to be fully deployable to every type of employee in an enterprise, requiring no external system integration,
and is administered entirely within the app. Feature sets are intended to be configurable to individual customer needs, allowing organizations
to adapt our solution to their workflows and rapidly realize value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our relentless focus on innovation, speed, and
user impact underpins Amesite&rsquo;s mission to stay ahead of the curve, helping drive customer satisfaction, adoption, and business
performance across rapidly evolving market segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have received fourteen U.S. patents (11 utility,
3 design) and currently have one pending U.S. patent applications, including one to cover the artificial intelligence platform, and others
related to security, power consumption, blockchain, design and other technologies, including methods and systems related to learning systems
and methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We endeavor to protect our source codes, methodologies,
algorithms, and techniques directed to other aspects of our artificial intelligence learning platform using our trade secret rights. We
have also registered our trademarks at the United States Patent and Trademark Office for AMESITE<SUP>&reg;</SUP>, KEEP LEARNING<SUP>&reg;,</SUP>&nbsp;and
LEARNING COMMUNITY ENVIRONMENT<SUP>&reg;</SUP>, as well as have pending trademark applications for PREACTO&trade; and NURSEMAGIC&#8480;.
We have also secured domain names, including amesite.com, amesite.co, amesite.net, and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our focus is on maximizing the impact and reach
of NurseMagic&trade; in healthcare and offering greater value than our competitors in the healthcare space. At the same time, we retain
the expertise and capability to further develop Amesite Engage or other solutions as market opportunities arise or demand shifts. The
healthcare software market is comprised of several distinct segments, each defined by the capabilities and focus of competing companies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Electronic Medical Record (EMR) or Electronic Health Record (EHR)
Firms</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These established firms deliver comprehensive
platforms deeply integrated across care operations. Their primary strengths lie in robust compliance frameworks, scalability, and breadth
of features.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Mid-Market and Specialized Vendors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These companies offer focused solutions in documentation,
compliance, or operations, often deploying new technologies rapidly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AI-First Entrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A newer class of digital health innovators provide
lightweight, AI-driven tools targeting workflow automation, documentation, and user experience. Their products are easy to onboard and
well-received by practitioners, but scaling compliance, security, and ROI claims for system-wide adoption present challenges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Niche Clinical Tools</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vendors in this category tailor solutions to specific
care settings&mdash;such as home health or assisted living&mdash;delivering specialized, regulatory-ready features.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NurseMagic&trade; has been designed to be at the
intersection of these segments, combining rapid deployment, practitioner-driven design, and robust compliance to meet evolving needs in
post-acute care. We believe that our adoption rates and enterprise wins suggest our focus on real workflow impact, security, and regulatory
alignment is resonating. Our continued success will depend on maintaining speed, responsiveness, and disciplined execution in an industry
defined by complexity and rapid change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation and Product Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal focus is on delivering NurseMagic&trade;
to the healthcare sector, and we are dedicated to maintaining full compliance with all applicable laws and regulations across every market
we serve or may enter. The healthcare industry is subject to extensive regulatory oversight at both the federal and state levels, demanding
strict standards for patient privacy, data security, clinical quality, and marketing practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our solutions target diverse care settings&mdash;such
as skilled nursing, assisted living, memory care, home health, and rehabilitation&mdash;and are therefore subject to a broad array of
regulatory requirements. These include, but are not limited to, compliance with the Health Insurance Portability and Accountability Act
(HIPAA), the HITECH Act, and relevant standards set by the Centers for Medicare &amp; Medicaid Services (CMS). We also closely monitor
evolving state regulations, such as those governing data privacy, breach notification, record retention, and specific clinical protocols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to laws directly governing healthcare
delivery, our activities&mdash;including those involving direct-to-consumer offerings&mdash;are regulated by federal and state consumer
protection, data privacy, and marketing laws. Oversight by bodies such as the Federal Trade Commission (FTC) and the U.S. Department of
Health and Human Services (HHS) is rigorous, and includes scrutiny of data usage, patient or end-user consent, and representations made
in our product marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amesite&rsquo;s business is built on continuous
monitoring of regulatory developments and proactive efforts to ensure all activities&mdash;whether relating to our current healthcare
offerings or to further market expansions&mdash;are fully compliant with the latest requirements. We recognize that lapses in regulatory
compliance by us or our clients have the potential to result in penalties, legal liability, or restrictions on operations. As such, we
partner closely with our customers and advisors to safeguard ongoing compliance, prepare for regulatory changes, and support all necessary
approvals for the use of our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In FY 2025, Amesite&rsquo;s sales and marketing
approach centered on high-velocity onboarding, delivery of scalable product tiers, and digital-first brand building. Amesite&rsquo;s sales
and marketing strategy is crafted to maximize the reach and value of NurseMagic&trade; in healthcare, while maintaining flexibility to
pursue additional segments as new opportunities emerge. In FY 2025, we streamlined our approach, making it easier for both individuals
and organizations to discover, adopt, and scale NurseMagic&trade; through self-service onboarding and clear, tiered offerings. We must
continue to refine and improve our strategy and tactics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NurseMagic&trade; Offerings and Onboarding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NurseMagic&trade; is available in multiple subscription
tiers to meet the broad spectrum of customer needs&mdash;from individual nurses and small care teams to large healthcare enterprises.
Individual users and team leads can initiate a 7-day free trial via a simple, self-purchase process, with plans that scale based on team
size and organizational requirements. For enterprises, we offer both standard and customized models, allowing for rapid and broad implementation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Organizations access NurseMagic&trade; through
a self-service onboarding process, allowing them to rapidly deploy the solution across their teams without the need for preliminary pilot
programs. This model empowers healthcare businesses to quickly realize benefits such as reduced documentation burdens, greater staff efficiency,
and enhanced patient care. Our flexible pricing and robust support, supported by internal estimates of substantial ROI primarily from
time savings, make large-scale adoption possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Market Engagement and Brand Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our awareness and adoption efforts are rooted
in targeted digital marketing, social media engagement, and partnerships with healthcare influencers. Amesite leverages a growing online
community&mdash;now exceeding 37,000 followers&mdash;to build NurseMagic&trade;&rsquo;s reputation and credibility. User testimonials
and advocacy from practitioners not only reinforce our brand but also accelerate word-of-mouth growth and drive further enterprise interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board of Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dennis Bernard, Chairman of the Board of Advisors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Bernard is the founder and President of Bernard
Financial Group and Bernard Financial Servicing Group (&ldquo;BFG&rdquo;). BFG is the largest commercial mortgage banking firm in Michigan,
financing, on average, over $1.0 billion annually. Mr. Bernard has been involved with over 1,200 commercial real estate financial transactions
totaling over $18.6 billion. Mr. Bernard specializes in both debt and equity placement with commercial lenders and institutional joint
venture participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Martha A. Darling, Member</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over the past 22 years, Ms. Darling has held volunteer
leadership roles nationally and in Michigan and has consulted on education policy issues for the National Academy of Sciences and other
non-profit organizations. Prior to moving to Ann Arbor, Ms. Darling was a Senior Program Manager at The Boeing Company in Seattle, from
which she retired in 1998. She joined Boeing in 1987, with assignments in 747 Program Management, Government Affairs and Boeing&rsquo;s
Corporate Offices, where she supported the chief executive officer and other executives. Previously, she was Vice President for Strategic
Planning at Seattle-First National Bank and then, on loan from Seattle-First, she served as Executive Director of the Washington Business
Roundtable&rsquo;s Education Study. From 1977 to 1982 she served in Washington, D.C. as White House Fellow and Executive Assistant to
Secretary of the Treasury W. Michael Blumenthal and then as Senior Legislative Aide to U.S. Senator Bill Bradley. She has also served
as Special Assistant to the Governor of Washington, Research Social Scientist at the Battelle Seattle Research Center, and was a free-lance
consultant to the Organization for Economic Cooperation and Development and other international organizations for four years in Paris.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Theodore l. Spencer, Member</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Spencer is Senior Advisor on Admissions Outreach
at the University of Michigan. Prior to September 2014, he was Associate Vice Provost and Executive Director of Undergraduate Admissions.
Before joining Michigan in 1989, he was an Associate Director of Admissions at the United States Air Force Academy. He is a graduate of
the Military Air War College and was one of thirty-five Air Force recruiting commanders in the United States. He is a retired Lieutenant
Colonel in the United States Air Force. Early in his career, he was a salesman for the IBM Corporation in the City of Detroit. Ted has
presented at numerous professional conferences state-wide, nationally and internationally, and has written and published articles on the
college admissions process. He has received numerous awards and was recognized as the Point Man on Diversity Defense for affirmative action
in college admissions. He has previously served as a Trustee for the College Board and on the faculty for the Harvard Summer Institute
on College Admissions. Ted holds a M.S. degree in sociology from Pepperdine University and a B.S. in political science from Tennessee
State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Human Capital Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General Information About Our Human Capital
Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, we have 6 full-time employees
and 2 consultants. We intend to engage consultants in general administration on an as-needed basis. We also intend to engage experts in
operations, finance and general business to advise us in various capacities. None of our employees are covered by a collective bargaining
agreement, and we believe our relationship with our employees is good to excellent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Culture</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amesite&rsquo;s mission is to empower people with
AI tools. We believe that supporting our team with a wonderful environment supports and powers us to accomplish our goals. Our values
are summarized in our beats-the guideposts for our culture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgment beats rules</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measurement beats conjecture</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Humility beats arrogance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Honesty beats politeness</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Growth beats comfort</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transparency beats manipulation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Passion beats indifference</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated in November 2017.
The Company is Amesite Inc. (Nasdaq: AMST) is a pioneering technology company specializing in the development and marketing of B2C and
B2B AI-driven solutions, including its higher ed platform that offers professional learning. Leveraging its proprietary AI infrastructure,
Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagic&trade;, the Company&rsquo;s
mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized
guidance to nurses on patient care, medications, and handling challenging workplace situations. The Company&rsquo;s activities are subject
to significant risks and uncertainties. The Company&rsquo;s operations are in two segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 18, 2020, we consummated a reorganizational
merger (the &ldquo;Reorganization&rdquo;), pursuant to an Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;), dated July
14, 2020, whereby Amesite Inc. (&ldquo;Amesite Parent&rdquo;), our former parent corporation, merged with and into us, with our Company
resulting as the surviving entity. In connection with the same, we filed a Certificate of Ownership and Merger with the Secretary of State
of the State of Delaware, and changed our name from &ldquo;Amesite Operating Company&rdquo; to &ldquo;Amesite Inc.&rdquo; The stockholders
of Amesite Parent approved the Merger Agreement on August 4, 2020. The directors and officers of Amesite Parent became our directors and
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, on the Effective
Date, each share of Amesite Parent&rsquo;s common stock, $0.0001 par value per share, issued and outstanding immediately before the Effective
Date, was converted, on a one-for-one basis, into shares of our common stock. Additionally, each option or warrant to acquire shares of
Amesite Parent outstanding immediately before the Effective Date was converted into and became an equivalent option to acquire shares
of our common stock, upon the same terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters are located at 607
Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, and our telephone number is (734) 876-8130. We maintain a website at www.amesite.com.
The contents of, or information accessible through, our website is not part of this Annual Report on Form 10-K, and our website address
is included in this document as an inactive textual reference only. We make our filings with the SEC, including our Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, available free of charge on
our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the SEC. The public may read
and copy the materials we file with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The
public may also obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Additionally, the
SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&rsquo;s
website is www.sec.gov. The information contained in the SEC&rsquo;s website is not intended to be a part of this filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_20"></A>DESCRIPTION OF OUR CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of shares of our common stock are
entitled to one vote per share on all matters to be voted upon by our stockholders, provided, however, that, except as otherwise required
by law, holders of our common stock shall not be entitled to vote on any amendment to our certificate of incorporation that relates solely
to the terms of one or more outstanding series of our preferred stock if the holders of such affected series of preferred stock are entitled,
either separately or together as a class with the holders of one or more other series of preferred stock, to vote thereon by law or pursuant
to our certificate of incorporation. There are no cumulative rights with respect to our common stock. Subject to preferences that may
be applicable to any outstanding preferred stock, the holders of shares of our common stock are entitled to receive ratably any dividends
that may be declared from time to time by our board of directors out of funds legally available for that purpose. In the event of our
liquidation, dissolution or winding up, the holders of shares of our common stock are entitled to share ratably in all assets remaining
after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Our common stock has no preemptive
or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock.
The outstanding shares of our common stock are fully paid and non-assessable, and any shares of our common stock to be issued upon an
offering pursuant to this prospectus will be fully paid and nonassessable upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid cash dividends on our common
stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination
about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital
requirements, operating and financial conditions and on such other factors as our board of directors deems relevant. For a discussion
of provisions in our charter that would have an effect of delaying or preventing a change of control, see &ldquo;<I>Anti-Takeover Effects
of Provisions of Our Charter Documents.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of our preferred stock
and the description of the terms of any particular series of our preferred stock that we choose to issue are not complete. These descriptions
are qualified in their entirety by reference to our certificate of incorporation and a certificate of designation, if and when adopted
by our board of directors, relating to that series. The rights, preferences, privileges and restrictions of the preferred stock of each
series will be fixed by the certificate of designation relating to that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no shares of preferred stock
outstanding. Our board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of
preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred
stock. Any or all of these rights may be greater than the rights of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors, without stockholder approval,
can issue preferred stock with voting, conversion or other rights that could negatively affect the voting power and other rights of the
holders of our common stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control
of us or make it more difficult to remove our management. Additionally, the issuance of preferred stock may have the effect of decreasing
the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may specify the following
characteristics of any preferred stock, which may affect the rights of holders of our common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the annual dividend rate, if any, whether the dividend rate is fixed or variable, the date or dates on which dividends will accrue, the dividend payment dates, and whether dividends will be cumulative;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
liquidation preference, if any, and any accumulated dividends upon the liquidation, dissolution or winding up of our affairs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
voting rights; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
or all other preferences and relative, participating, optional or other special rights, privileges or qualifications, limitations or
restrictions.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series A-1 Warrants and Series A-2 Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material terms
of our Series A-1 Warrants and Series A-2 Warrants (collectively, the &ldquo;Common Warrants&rdquo;). This summary does not purport to be
complete and is qualified in its entirety by reference to the forms of the Series A-1 Warrant and the Series A-2 Warrant, copies of which
were filed as Exhibits 4.2 and 4.3, respectively, to our Current Report on Form 8-K filed with the SEC on April 28, 2026, and are incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our concurrent private placement
that closed on April 28, 2026, we issued Series A-1 Warrants to purchase an aggregate of 1,393,732 shares of Common Stock and Series A-2
Warrants to purchase an aggregate of 1,393,732 shares of Common Stock to certain institutional investors. In addition, we issued Series
A-1 Warrants to purchase an aggregate of 418,118 shares of Common Stock and Series A-2 Warrants to purchase an aggregate of 418,118 shares
of Common Stock to certain of our officers and directors, including Dr. Ann Marie Sastry, Ph.D, our Chairman and Chief Executive Officer,
and George Parmer, a member of our board of directors, in connection with the Insider-Led Private Placement that closed on April 28, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercisability </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants have an exercise price of
$1.435 per share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants will be exercisable beginning
on the date on which we obtain stockholder approval (the &ldquo;Stockholder Approval Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Term</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A-1 Warrants will expire five years
after the later of (i) the effective date of the resale registration statement registering the shares of Common Stock issuable upon exercise
of the Common Warrants (the &ldquo;Resale Registration Statement&rdquo;) and (ii) the Stockholder Approval Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A-2 Warrants will expire eighteen months
after the later of (i) the effective date of the Resale Registration Statement and (ii) the Stockholder Approval Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cashless Exercise</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants may be exercised on a cashless
basis if, at the time of exercise, there is no effective registration statement registering, or the prospectus contained therein is not
available for, the resale of the shares of Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Adjustments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise price of the Common Warrants is subject
to customary adjustments in the event of stock splits, stock dividends, and similar recapitalization transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Beneficial Ownership Limitation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants issued to our institutional
investors contain beneficial ownership limitations which provide that we shall not effect any exercise, and a holder shall not have the
right to exercise, any portion of a Common Warrant to the extent that, after giving effect to such exercise, the holder (together with
such holder&rsquo;s affiliates) would beneficially own in excess of 4.99% of the number of shares of Common Stock outstanding immediately after
giving effect to the issuance of shares issuable upon such exercise. This limitation may be waived (up to a maximum of 9.99%) by a holder
in its sole discretion upon not less than sixty-one (61) days&rsquo; prior notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>No Listing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants are not listed on any national
securities exchange or other trading market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>No Rights as a Stockholder</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Common Warrants do not have the rights
or privileges of holders of our Common Stock, including any voting rights, until they exercise their Common Warrants and receive shares
of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Registration Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the Common
Warrants, we entered into a registration rights agreement with certain institutional investors pursuant to which we agreed to prepare
and file a registration statement with the SEC registering the resale of the shares of Common Stock issuable upon exercise of the Common
Warrants no later than 15 days after the date of the registration rights agreement, and to use our best efforts to have such registration
statement declared effective no later than 30 days after the date of the registration rights agreement (or 60 days following the date
of the registration rights agreement in the event of a &ldquo;full review&rdquo; by the SEC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Provisions of Our
Charter Documents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation provides for
our board of directors to be divided into three classes serving staggered terms. Approximately one-third of the board of directors will
be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of our outstanding
voting stock from obtaining control of our board of directors until the second annual stockholders meeting following the date the acquirer
obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer
or otherwise attempting to obtain control of us and could increase the likelihood that incumbent directors will retain their positions.
Our certificate of incorporation provides that directors may be removed with cause by the affirmative vote of the holders of a majority
of the voting power of all of our outstanding stock or without cause by the affirmative vote of the holders of at least 66 and 2/3% of
the voting power of all of our outstanding stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation provides that
certain amendments of our certificate of incorporation and amendments by our stockholders of our bylaws require the approval of at least
66 and 2/3% of the voting power of all of our outstanding stock. These provisions could discourage a potential acquirer from making a
tender offer or otherwise attempting to obtain control of our company and could delay changes in management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation also provides
that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive
forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by
any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision
of the General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim that is governed by the
internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named
as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court
of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. This forum selection provision may limit our
stockholders&rsquo; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers,
employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action,
if successful, might benefit our stockholders. Notwithstanding the foregoing, the exclusive provision shall not preclude or contract the
scope of exclusive federal or concurrent jurisdiction for actions brought under the Exchange Act, or the Securities Act, or the respective
rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, our certificate of incorporation
and bylaws provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of
the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under
the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company are
deemed to have notice of and consented to this provision.&nbsp;The Supreme Court of Delaware has held that this type of exclusive federal
forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce such provision,
if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws establish an advance notice procedure
for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election
to our board of directors. At an annual meeting, stockholders may only consider proposals or nominations specified in the notice of meeting
or brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination
by a person who was a stockholder at the time of giving notice and at the time of the meeting, who is entitled to vote at the meeting
and who has complied with the notice requirements of our bylaws in all respects. The bylaws do not give our board of directors the power
to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual
meeting of our stockholders. However, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the
proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation
of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise attempting to obtain control of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws provide that a special meeting of our
stockholders may be called only by our Secretary and at the direction of our board of directors by resolution adopted by a majority of
our board of directors. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder
consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time
as a majority of our board of directors, the chairperson of our board of directors, the president or the chief executive officer believed
the matter should be considered or until the next annual meeting&nbsp;<I>provided</I>&nbsp;that the requestor met the notice requirements.
The restriction on the ability of stockholders to call a special meeting means that a proposal to replace our board of directors also
could be delayed until the next annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws do not allow our stockholders to act
by written consent without a meeting. Without the availability of stockholder action by written consent, a holder controlling a majority
of our capital stock would not be able to amend our bylaws or remove directors without holding a stockholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the provisions of Section 203
of the General Corporation Law, or Section 203. Under Section 203, we would generally be prohibited from engaging in any business combination
with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder
unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
to this time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming
an interested stockholder;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
at least 85% of our voting stock outstanding at the time the transaction commenced, excluding shares owned by persons who are directors
and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether
shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
or subsequent to such time, the business combination is approved by our board of directors and authorized at an annual or special meeting
of stockholders, and not by written consent, by the affirmative vote of at least 66 and 2/3% of the outstanding voting stock that is
not owned by the interested stockholder.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 203, a &ldquo;business combination&rdquo;
includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
merger or consolidation involving the corporation and the interested stockholder;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder,
subject to limited exceptions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of
the corporation beneficially owned by the interested stockholder; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, Section 203 defines an interested
stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or
person affiliated with or controlling or controlled by such entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of Delaware law and our certificate
of incorporation and bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they
may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in management. It is possible that these provisions may make
it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following such time, if any, as our capital stock
is listed on a national securities exchange or is held of record by more than 2,000 stockholders, we will be subject to the provisions
of Section 203 of the Delaware General Corporation Law, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market under the symbol &ldquo;AMST&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our transfer agent is Continental Stock Transfer
&amp; Trust Company, or CST. CST&rsquo;s address is 1 State Street 30th Floor, New York, NY 10004-1561 and its telephone number is (212)
845-3215.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Stock being offered by the Selling
Stockholders are those issuable to the Selling Stockholders, upon exercise of the Warrants. We are registering the shares of Common Stock
in order to permit the Selling Stockholders to offer the shares for resale from time to time. Except for the ownership of the Warrants
and as noted below, the Selling Stockholders have not had any material relationship with us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below lists the Selling Stockholders
and other information regarding the beneficial ownership of the shares of Common Stock by each of the Selling Stockholders. The second
column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder, based on its ownership of the shares
of Common Stock and Warrants, as of May 1, 2026, assuming exercise of the Warrants held by the Selling Stockholders on that date, without
regard to any limitations on exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third column lists the shares of Common Stock
being offered by this prospectus by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the terms of a registration
rights agreement with the Selling Stockholders, this prospectus generally covers the resale of the maximum number of shares of Common
Stock issuable upon exercise of the Warrants, determined as if the outstanding Warrants were exercised in full as of the trading day immediately
preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the
applicable date of determination and all subject to adjustment as provided in the registration rights agreement, without regard to any
limitations on the exercise of the Warrants. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders
pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Warrants, a Selling Stockholder
may not exercise the Warrants to the extent such exercise would cause such Selling Stockholder, together with its affiliates and attribution
parties, to beneficially own a number of shares of Common Stock which would exceed 4.99% of our then outstanding Common Stock following
such exercise, excluding for purposes of such determination shares of Common Stock issuable upon exercise of such Warrants which have
not been exercised. The number of shares in the second and fourth columns do not reflect this limitation. The Selling Stockholders may
sell all, some or none of their shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of<BR> Shares<BR> of Common<BR> Stock<BR> Beneficially<BR> Owned<BR> Prior to<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<BR> Number of<BR> Shares<BR> of Common<BR> Stock<BR> to be Sold<BR> in this<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares<BR> of Common<BR> Stock<BR> Beneficially<BR> Owned After<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage<BR> of Shares<BR> Beneficially<BR> Owned after<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital Master Fund Ltd. <SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,742,165</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,742,165</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intracoastal Capital LLC <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,742,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,742,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Ann Marie Sastry</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,398,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">522,648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">875,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.66</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">George Parmer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,054,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">731,706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.20</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Augustus Trading LLC<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Rubinstein<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilson Drive Holdings LLC<SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,292</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,292</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles Worthman<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">less than 1%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The ability to exercise the Warrants held by the Selling Stockholders is subject to a beneficial ownership limitation that, at the time of initial issuance of the Warrants was capped at 4.99% (or at the election of the holder, 9.99%) beneficial ownership of the Company&rsquo;s issued and outstanding Common Stock (post-exercise). These beneficial ownership limitations may be adjusted up or down, subject to providing advanced notice to the Company. Beneficial ownership as reflected in the selling stockholder table reflects the total number of shares potentially issuable underlying the Warrants and does not give effect to these beneficial ownership limitations. Accordingly, actual beneficial ownership, as calculated in accordance with Section 13(d) and Rule 13d-3 thereunder may be lower than as reflected in the table.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &ldquo;Master Fund&rdquo;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&ldquo;Armistice Capital&rdquo;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. As of April 29, 2026, this includes an aggregate of: (1) 348,433 shares of Common Stock underlying Pre-Funded Warrants (such Pre-Funded Warrants are subject to a beneficial ownership limitation of 9.99%); (2) 696,866 shares of Common Stock underlying Series A-1 Warrants and (3) 696,866 shares of Common Stock underlying Series A-2 Warrants. Each of the Series A-1 Warrants and Series A-2 Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the Series A-1 Warrants or Series A-2 Warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of Common Stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Mitchell P. Kopin (&ldquo;Mr. Kopin&rdquo;) and Daniel B. Asher (&ldquo;Mr. Asher&rdquo;), each of whom are managers of Intracoastal Capital LLC (&ldquo;Intracoastal&rdquo;), have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) of the securities reported herein that are held by Intracoastal. As of April 29, 2026, this includes an aggregate of: (1) 348,433 shares of Common Stock underlying Pre-Funded Warrants (such Pre-Funded Warrants are subject to a beneficial ownership limitation of 9.99%); (2) 696,866 shares of Common Stock underlying Series A-1 Warrants and (3) 696,866 shares of Common Stock underlying Series A-2 Warrants. Each of the Series A-1 Warrants and Series A-2 Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the Series A-1 Warrants or Series A-2 Warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of Common Stock in excess of the beneficial ownership limitation. The address of Intracoastal Capital LLC is 2211A Lakeside Drive, Bannockburn, IL 60015.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Orsium Capital LLC, the authorized agent to Augustus Trading LLC, has discretionary authority to vote and dispose of the securities held by Augustus Trading LLC and may be deemed to be the beneficial owner (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of these securities. Olivier Morali, in his capacity as managing member of Orsium Capital LLC, may also be deemed to have investment discretion and voting power over the shares held by Augustus Trading LLC. Orsium Capital LLC and Mr. Morali each disclaims any beneficial ownership of these securities. The address of Augustus Trading LLC is 600 Lexington Avenue, 32nd Floor, New York, NY 10022.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify">Each of the Selling Stockholders is affiliated with H.C. Wainwright
&amp; Co., LLC, a registered broker-dealer and has a registered address of c/o H.C. Wainwright &amp; Co., 430 Park Ave, 3rd Floor, New
York, NY 10022, and has sole voting and dispositive power over the securities held. The Selling Stockholder acquired the Placement Agent
Warrants in the ordinary course of business and, at the time the Placement Agent Warrants were acquired, the Selling Stockholder had no
agreement or understanding, directly or indirectly, with any person to distribute such securities.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The securities are held by Wilson Drive Holdings LLC with a registered address of 600 Lexington Avenue, 32nd Floor, New York, NY 10022. Craig Schwabe is the managing member Wilson Drive Holdings LLC and has the power to vote and dispose the securities held. Neither Wilson Drive Holdings LLC nor Mr. Schwabe is a broker-dealer. Mr. Schwabe is affiliated with the following registered broker-dealers: H.C. Wainwright &amp; Co., LLC, Rodman &amp; Renshaw LLC and Stockblock Securities LLC. The securities were acquired in the ordinary course of business and, at the time the securities were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities. Mr. Schwabe has not held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Selling Stockholder of the securities and
any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby
on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private
transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods
when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as
principal to facilitate the transaction;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
negotiated transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
of short sales;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated
price per security;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
combination of any such methods of sale; or</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other method permitted pursuant to applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may also sell securities
under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
if available, rather than under this prospectus. Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers
to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts
as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to
this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule
2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of the securities
or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders
may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers
or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other
financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders and any broker-dealers
or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder
has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute
the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required to pay certain fees and expenses
incurred by us incident to the registration of the securities. We have agreed to indemnify the Selling Stockholders against certain losses,
claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We agreed to keep this prospectus effective until
the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard
to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for us to be in compliance with the current
public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been
sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will
be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain
states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under applicable rules and regulations under the
Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities
with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution.
In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder,
including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other
person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy
of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the issuance of the shares of
common stock offered by us in this offering will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statement as of, and for the year
ended June 30, 2025, included in our Annual Report on Form 10-K/A for the year ended June 30, 2025 and incorporated by reference in this
registration statement, have been so incorporated by reference in reliance upon the report of Novogradac &amp; Company LLP, independent
registered public accountants, upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statement as of, and for the year
ended June 30, 2024, included in our Annual Report on Form 10-K/A for the year ended June 30, 2025 and incorporated by reference in this
registration statement, have been so incorporated by reference in reliance upon the report of Turner, Stone &amp; Company, L.L.P, independent
registered public accountants, upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely
only on the information contained in this prospectus or incorporated by reference into this prospectus. We have not authorized anyone
else to provide you with different information. We are not making an offer of these securities in any jurisdiction where the offer is
not permitted. You should assume that the information contained in this prospectus, or any document incorporated by reference in this
prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any
sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public from commercial document retrieval services
and over the Internet at the SEC&rsquo;s website at <I>http://www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain a website at <I>www.amesite.com</I>.
You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably
practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed
through, our website is not incorporated by reference into, and is not part of, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><B>INCORPORATION OF DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of the registration statement,
but the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to &ldquo;incorporate
by reference&rdquo; the information contained in documents we file with the SEC, which means that we can disclose important information
to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference
is considered to be part of this prospectus and you should read it with the same care that you read this prospectus. Information that
we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference,
in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference the documents listed
below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus form
a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that
all securities covered by this prospectus have been sold; provided, however, that we are not incorporating that any information furnished
under either Item 2.02 or Item 7.01 of any Current Report on Form 8-K and exhibits furnished on such incorporating form that relate to
such items:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025093213/ea0254427-10k_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended June 30, 2025, filed with the SEC on September 29, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Amendment to our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025103104/ea0262762-10ka1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K/A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended June 30, 2025, filed with the SEC on October 28, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Reports on Form 10-Q for the quarters ended September 30, 2025 and December 31, 2025, filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025102257/ea0261871-10q_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 24, 2025</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026012916/ea0274215-10q_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 6, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on Form 8-K filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025103511/ea026299501-8k_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></A> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025103769/ea0263127-8k_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 30, 2025</FONT></A>, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026045782/ea0287089-8k_amesite.htm">April 21, 2026</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026048326/ea0287970-8k_amesite.htm">April 28, 2026</A>; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our common stock contained in our Registration Statement on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390020028010/ea127237-8a12b_amesiteinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 8-A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed with the SEC on September 23, 2020, including any amendments or reports filed with the SEC for the purposes of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any statements made in a document incorporated
by reference in this prospectus are deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
in this prospectus or in any other subsequently filed document, which is also incorporated by reference, modifies or supersedes the statement.
Any statement made in this prospectus is deemed to be modified or superseded to the extent a statement in any subsequently filed document,
which is incorporated by reference in this prospectus, modifies or supersedes such statement. Any statement so modified or superseded
will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information relating to us contained in this
prospectus should be read together with the information in the documents incorporated by reference. In addition, certain information,
including financial information, contained in this prospectus or incorporated by reference in this prospectus should be read in conjunction
with documents we have filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each person, including any
beneficial holder, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the information
that has been incorporated by reference in the prospectus but not delivered with the prospectus. Requests for documents should be by writing
to or telephoning us at the following address: Amesite Inc., 607 Shelby Street, Suite 700 PMB 214, Detroit, MI 48226, (734) 876-8141.
Exhibits to these filings will not be sent unless those exhibits have been specifically incorporated by reference in such filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4,836,245 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea028973301_img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amesite Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II&mdash;INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all expenses, other
than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities being registered.
All the amounts shown are estimates except the SEC registration fee and the FINRA filing fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount to be <BR> paid</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">674.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,000.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">60,674.56</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14. Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 102 of the DGCL permits a corporation
to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach
of fiduciary duty as a director, except where the director breached his/her duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate
law or obtained an improper personal benefit. Our Certificate of Incorporation provides that no director of the Company shall be personally
liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of
law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for
breaches of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 145 of the DGCL provides that a corporation
has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation
for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit
or proceeding to which he/she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit
or proceeding by reason of such position, if such person acted in good faith and in a manner he/she reasonably believed to be in or not
opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his/her
conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made
with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and
only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in
view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court
of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation and Bylaws provide
indemnification for our directors and officers to the fullest extent permitted by the DGCL. We will indemnify each person who was or is
a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or
in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving,
or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &ldquo;Indemnitee&rdquo;),
or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&rsquo; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and
any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to,
our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct
was unlawful. Our Certificate of Incorporation and Bylaws provide that we will indemnify any Indemnitee who was or is a party to an action
or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed
to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director or officer of another corporation,
partnership, joint venture, trust or other enterprise, or who was an employee or agent of a predecessor corporation or another enterprise
at the request of such predecessor corporation, against all expenses (including attorneys&rsquo; fees) and, to the extent permitted by
law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, except that no indemnification
shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a
court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of
such expenses. Expenses must be advanced to an Indemnitee under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with each of our directors and executive officers. Each indemnification agreement provides, among other things, for indemnification
to the fullest extent permitted by law and our Certificate of Incorporation and Bylaws against any and all expenses, judgments, fines,
penalties and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses
to the indemnitee and for the reimbursement to us if it is found that such indemnitee is not entitled to such indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain a general liability insurance policy
that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their
capacities as directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is information regarding securities
issued by us since during the prior three years that were not registered under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2025, 121,250 options
to purchase common stock were issued to employees under our 2018 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing issuances were exempt from registration
under Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2024; 6,292 options
to purchase common stock were issued to employees under our 2018 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing issuances were exempt from registration
under Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2023, 999 options
to purchase common stock were issued to employees under our 2018 Equity Incentive Plan and 14,083 shares of common stock were issued to
consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing issuances were exempt from registration
under Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed<BR>
with this</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated by Reference</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 7%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 48%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Title</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form S-1</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File No.</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 6%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date Filed</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390020025469/ea125860ex2-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger and Reorganization, dated April 26, 2018, by and among Lola One Acquisition Corporation, Lola One Acquisition Sub, Inc., and Amesite Inc.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-248001</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390020025469/ea125860ex2-2_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Agreement and Plan of Merger and Reorganization, dated July 14, 2020, by and between Amesite Operating Company, a Delaware corporation, and Amesite Inc., a Delaware corporation</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-248001</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390020037381/f10q0920ex3-1_amesiteinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of the Registrant.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/16/2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390025044301/ea024165701ex3-4_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of the Registrant, as amended</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/15/2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390023002835/ea171681ex3-1_amesiteinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations of Series A Preferred Stock, dated January 13, 2023</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390023013326/ea173916ex3-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation of Amesite Inc. dated February 16, 2023</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/21/2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390022053249/ea165262ex4-1_amesiteinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390022053249/ea165262ex4-2_amesiteinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390023081208/f10k2023ex4-3_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registrant&rsquo;s Securities</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/6/2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390020025469/ea125860ex4-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Certificate</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282999</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/5/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390024108483/ea022437701ex4-2_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Senior Debt Indenture, between the Company and one or more trustees to be names</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282999</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/13/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390024108483/ea022437701ex4-3_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Subordinated Debt Indenture, between the Company and one or more trustees to be named</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-282999</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/13/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390025002639/ea022707301ex4-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriters&rsquo; Warrant</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex4-1.htm">Form of Pre-Funded Warrant</A></U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex4-2.htm">Form of Series A-1 Warrant</A></U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex4-3.htm">Form of Series A-2 Warrant</A></U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex4-4.htm">Form of Placement Agent Warrant</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="ea028973301ex5-1.htm">Opinion of Sheppard, Mullin, Richter &amp; Hampton LLP</A></U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390020025469/ea125860ex10-7_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 Equity Incentive Plan and forms of award agreements thereunder, assumed in the Reorganization</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-248001</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390020025469/ea125860ex10-8_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018 Equity Incentive Plan and forms of award agreements thereunder, assumed in the Reorganization.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-248001</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390023013326/ea173916ex10-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Amesite Inc. 2018 Equity Incentive Plan</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/21/2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390024112030/ea022571301ex4-3_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Amesite Inc. 2018 Equity Incentive Plan</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-284031</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/23/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390024083458/ea021487001ex10-4_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amesite Inc. Deferred Fee Plan</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/30/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390024102861/ea022266901ex10-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Berman CFO Agreement</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390025002639/ea022707301ex1-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated January 7, 2025, by and between the Company and Laidlaw &amp; Company (UK) Ltd., as representative of the several underwriters listed in Schedule I thereto</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex10-1.htm">Form of RD Securities Purchase Agreement</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex10-2.htm">Form of PIPE Securities Purchase Agreement</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390026048326/ea028797001ex10-3.htm">Form of Registration Rights Agreement</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">002-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/28/2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390025058420/ea024693001ex16-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter from Turner, Stone &amp; Company, L.L.P. dated June 24, 2025</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/26/2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390024083458/ea021487001ex19-1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amesite Inc. Insider Trading Compliance Program</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39553</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/30/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea028973301ex23-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Novogradac &amp; Company LLP</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea028973301ex23-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Turner, Stone, &amp; Co., LLP</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea028973301ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sheppard, Mullin,
    Richter &amp; Hampton LLP (included in Exhibit 5.1)</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#POW"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included
    on the signature page to this registration statement)</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="ea028973301ex-fee.htm">Filing Fee Table</A></U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management contract or compensatory plan or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because such information is both not material and is the type that the Company treats as private or confidential.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To include any material information with respect
    to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration
    statement;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided, however, that paragraphs (i), (ii) and
    (iii) do not apply if the registration statement is on Form S-1 and the information required to be included in a post-effective amendment
    by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section
    15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form
    of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the
undersigned registrant;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="POW"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Detroit, State of Michigan, on May 12, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMESITE INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Ann Marie Sastry</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ann Marie Sastry, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KNOW ALL MEN BY THESE PRESENTS, that each person
whose signature appears below constitutes and appoints Ann Marie Sastry, Ph.D., his/her true and lawful attorney-in-fact and agent with
full power of substitution and re-substitution, for him/her and in his/her name, place and stead, in any and all capacities to sign any
or all amendments (including, without limitation, post-effective amendments) to this Registration Statement, any related Registration
Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and any or all pre- or post-effective amendments
thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully for all intents and purposes as he or she might or could do in person, hereby
ratifying and confirming that said attorney-in-fact and agent, or any substitute or substitutes for him, may lawfully do or cause to be
done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following persons in the capacities
and on the dates indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; text-align: center"><B>Signature</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; border-bottom: black 1.5pt solid; text-align: center"><B>Title</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 23%; border-bottom: black 1.5pt solid; text-align: center"><B>Date</B></TD></TR>
  <TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><I>/s/ Ann Marie Sastry&nbsp;</I></TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer, President and Chairman of the Board</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 12, 2026</TD></TR>
  <TR>
    <TD>Ann Marie Sastry, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>(<I>Principal Executive Officer)</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><I>/s/ Sarah Berman</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 12, 2026</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">Sarah Berman</TD>
    <TD>&nbsp;</TD>
    <TD><I>(Principal Financial Officer and Principal Accounting Officer)</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid"><I>/s/ Barbie Brewer</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 12, 2026</TD></TR>
  <TR>
    <TD>Barbie Brewer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid"><I>/s/ Michael Losh</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 12, 2026</TD></TR>
  <TR>
    <TD>Michael Losh</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid"><I>/s/ Gilbert S. Omenn</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 12, 2026</TD></TR>
  <TR>
    <TD>Gilbert S. Omenn, M.D., Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid"><I>/s/ George Parmer</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 12, 2026</TD></TR>
  <TR>
    <TD>George Parmer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea028973301ex5-1.htm
<DESCRIPTION>OPINION OF SHEPPARD, MULLIN, RICHTER & HAMPTON LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 60%; font-size: 10pt"><IMG SRC="ea028973301_ex5-1img1.jpg" ALT=""></TD>
    <TD STYLE="text-align: left; width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Sheppard, Mullin, Richter &amp; Hampton&nbsp;LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">30 Rockefeller Plaza</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">New York, New York 10112-0015</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">212.653.8700 main</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">212.653.8701 fax</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">www.sheppardmullin.com</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 12, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>VIA ELECTRONIC MAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Amesite
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">607 Shelby Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Suite 700, PMB 214</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Detroit, MI 48226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration Statement on Form S-1</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are acting as counsel
to <FONT STYLE="background-color: white">Amesite Inc.</FONT> (the &ldquo;Company&rdquo;) in connection with its registration statement
on Form S-1 (the &ldquo;Registration, Statement&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), relating to the Registration Statement on Form S-1 (the &ldquo;Registration
Statement&rdquo;) filed by the Company with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) under the Securities Act of
1933, as amended (the &ldquo;Securities Act&rdquo;). The Registration Statement covers the resale of 418,118 shares (the &ldquo;Shares&rdquo;)
of the Company&rsquo;s common stock, $0.0001 par value per share (&ldquo;Common Stock&rdquo;), consisting of (i) 418,118 shares of Common
Stock issued pursuant to a securities purchase agreement entered into by and between us and certain institutional investors dated April
27, 2026 (the &ldquo;Purchase Agreement&rdquo;), (ii) up to 696,866 shares of Common Stock issuable upon exercise of pre-funded warrants
(the &ldquo;Pre-Funded Warrants&rdquo;) issued pursuant to the Purchase Agreement, (iii) up to 1,811,850 shares of Common Stock issuable
upon exercise of Series A-1 warrants (the &ldquo;Series A-1 Warrants&rdquo;) issued pursuant to the Purchase Agreement, (iv) up to 1,811,850
shares of Common Stock issuable upon exercise of Series A-2 warrants (the &ldquo;Series A-2 Warrants&rdquo;) issued pursuant to the Purchase
Agreement, and (v) up to 97,561 shares of Common Stock issuable upon exercise of warrants (the &ldquo;Placement Agent Warrants) issued
pursuant to the engagement agreement dated as of April 26, 2026, by and between the Company and H.C. Wainwright &amp; Co., LLC (the &ldquo;Placement
Agent&rdquo;) The Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants and Placement Agent Warrants are collectively referred
to herein as the &ldquo;Warrants&rdquo;. T<FONT STYLE="background-color: white">his opinion letter is furnished to you at your request
to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K in connection with the Registration Statement.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">In
connection with this opinion, we have reviewed and relied upon the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Registration
Statement and the related prospectus included therein;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Certificate of Incorporation of the Company, as amended and in&nbsp;effect on the date hereof;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Bylaws of the Company in effect on the date hereof;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the form of Pre-Funded Warrant;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the form of Series A-1 Warrant;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The form of Series A-2 Warrant;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the form of Placement Agent Warrant;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the resolutions of the Board of Directors of the Company authorizing/ratifying the issuance and sale of the &nbsp;Warrants and the shares of Common Stock issuable upon exercise thereof, the preparation and filing of the Registration Statement, and other actions with regard thereto; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In our examination, we
have assumed the genuineness of all signatures, including endorsements, the legal capacity and competency of all natural persons, the
authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile,
electronic, certified or photocopy, and the authenticity of the originals of such copies. As to any facts relevant to the opinions stated
herein that we did not independently establish or verify, we have relied upon statements and representations of officers and other representatives
of the Company and others and of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><IMG SRC="ea028973301_ex5-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon, subject to
and limited by the foregoing, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Warrants have been duly authorized by all requisite corporate action on the part of the Company under the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Corporation Law of the State of Delaware <FONT STYLE="background-color: white">(&ldquo;DGCL&rdquo;)</FONT> and the laws of the State of New York <FONT STYLE="background-color: white">and, provided that the Warrants have been duly executed and delivered by the Company and duly delivered to the purchasers thereof against payment therefor, the Warrants, when issued and sold as contemplated in the Registration Statement will be valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles (regardless of whether such enforceability is considered in a proceeding at law or in equity).</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The shares of Common Stock issuable upon exercise of the Warrants (the &ldquo;Warrant Shares&rdquo;) have been duly authorized by all requisite corporate action on the part of the Company under the DGCL and the laws of the State of New York and, when the Warrant Shares are delivered to and paid for in accordance with the terms of the&nbsp;&nbsp;Warrants and when evidence of the issuance thereof is duly recorded in the Company&rsquo;s books and records, the Warrant Shares will be validly issued, fully paid and non-assessable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We also hereby consent
to <FONT STYLE="background-color: white">the filing of this opinion as an exhibit to the Registration Statement, and</FONT> to the reference
to our firm under the caption &ldquo;Legal Matters&rdquo; in the prospectus which forms part of the Registration Statement. In giving
this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Act, the rules
and regulations of the Commission promulgated thereunder or Item 509 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We express no opinion
as to matters governed by any laws other than the DGCL<FONT STYLE="background-color: white">&nbsp;and the laws of the State of New York</FONT>.
No opinion is expressed herein with respect to the qualification of the Securities under the securities or blue sky laws of any state
or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This opinion letter is
rendered as of the date first written above and we disclaim any obligation to advise you of facts, circumstances, events or developments
which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly
limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating
to the Company or the Securities, or any other agreements or transactions that may be related thereto or contemplated thereby. We are
expressing no opinion as to any obligations that parties other than the Company may have under or in respect of the Securities or as to
the effect that their performance of such obligations may have upon any of the matters referred to above. No opinion may be implied or
inferred beyond the opinion expressly stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sheppard, Mullin, Richter &amp; Hampton LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHEPPARD,
    MULLIN, RICHTER &amp; HAMPTON <FONT STYLE="text-transform: uppercase">LLP</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea028973301ex23-1.htm
<DESCRIPTION>CONSENT OF NOVOGRADAC & COMPANY LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt">We consent to the incorporation by reference in this Form S-1 Registration Statement of our report dated September 29, 2025 with respect
to the audited financial statements of Amesite Inc., which includes an explanatory paragraph related to the Company&rsquo;s ability to
continue as a going concern, appearing in the Annual Report on Form 10-K/A of the Company as of June 30, 2025 and for the year ended June
30, 2025.</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">We consent to the reference to us under the heading &ldquo;Experts&rdquo; in the Form S-1/A Registration Statement.</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">/s/ Novogradac &amp; Company LLP</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">Novogradac &amp; Company LLP</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">Plantation, Florida</P>

<P STYLE="margin: 0pt">May __, 2026</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ea028973301ex23-2.htm
<DESCRIPTION>CONSENT OF TURNER, STONE, & CO., LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><I>Your Vision Our Focus</I></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ea028973301_ex23-2img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference
in this Registration Statement on Form S-1 (the &ldquo;Registration Statement&rdquo;) of our report dated September 30, 2024, relating
to the financial statements of Amesite Inc. (the &ldquo;Company&rdquo;), which includes an explanatory paragraph relating to the Company&rsquo;s
ability to continue as a going concern, appearing in the Annual Report on Form 10-K/A of the Company for the year ended June 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to our firm under
the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ Turner, Stone &amp; Company, L.L.P.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Turner, Stone &amp; Company, L.L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dallas, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 11, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ea028973301ex-fee.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.4a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: ad23fc6405184604ec2cf73859a4c230 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">S-1</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0001807166</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001807166</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-05-07</xbrli:startDate>
          <xbrli:endDate>2026-05-07</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001807166</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-05-07</xbrli:startDate>
          <xbrli:endDate>2026-05-07</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">S-1</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">AMESITE INC.</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">4,836,245</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">4,884,607.45</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_016">674.45</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_017">4,884,607.45</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_018">674.45</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_019">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_020">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_021">674.45</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_022">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), based upon the average of the high and low prices for a share of the registrant&#8217;s common stock as reported on The Nasdaq Capital Market on May 4, 2026.<br/><br/>Pursuant to Rule 416 under the Securities Act, the shares of common stock offered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions.<br/><br/>Represents the resale of (i) 418,118 shares of common stock, (ii) up to 696,866 shares of common stock issuable upon exercise of pre-funded warrants, (iii) up to 1,811,850 shares of common stock issuable upon exercise of Series A-1 warrants, (iv) up to 1,811,850 shares of common stock issuable upon exercise of Series A-2 warrants, and (v) up to 97,561 shares of common stock issuable upon exercise of placement agent warrants.</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ea028973301_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028973301_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !B 0,# 2(  A$! Q$!_\0
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M-.,Y2;>B2B_/NO1"J9)+#WRF/\\T9 P >,XR%'KZC)QUSTK\</B5_P %V?\
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M3L[<]*$6K[M2DKW7,S0HI.@&3V'.?ZTM<?X?H>4%%%% !1110 4444 %%%%
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MXA_"[_@G]KOB[X8^.O%OPZ\36WQ*^&UG;>)?!7B#6/#'B,6!U^%)XTU?1?\
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MMV+#3-.TO2%9]5U+4=1<F***VA_>.[[=B(6.0'9/Y)_VU_\ @Y1O]-\4ZUX
M_8A\"Z+J^A:;=&SD^-7Q'LM3O-.\0$Y62;P5X,C,4S:*1M9/$_B>6-E.X?\
M"%2 "0_3/_!R%^T]XE^&O[*_PC^"'A;59])N?VC?$.HIXLEM%4_;/ ?@72-+
MUO7M%^5696\1>(M=\'0;E ?RWG5N7;'QS_P0@^#O[ /P]^%UI^T[^T-\2?@+
M+\>-;\0^*+/P+H7Q+\;^"[+4OAOX:T+5;KP\-6T?P_X@NHIXO$'B:5=5N)/%
M,.Y[CP?)X7@C:-1,:\+@SA+*,IX5K<=<1Y5/B*3K2PW#G#-*G.7M:E&I.A*5
M6-.+;BJE.:O+W(II.]TW^>^&7AKPIP[X?XCQ4XZR2MQLOKM;AOAGA2A&L^>O
M3J3I2Q%?V,).45*E-WFI0480E*,Y2A%_$]O_ ,%OO^"P'@Q;;XA^*;K[5X*6
M[*A_%W[/KV'@B^4]5&O:#X=\)$ \<#QCCKVX'[O_ /!-K_@O/\-_VNO%NB_!
M#X[>%].^#/QOUV/['X3N;#5&O_AY\2M27YGT?P]<:B([S0/$KJ"?^$7\1&4^
M4-L/BN[F=4;]3]7_ &MOV$O$&DWWA[7/VB_V9M5\.ZE8M:WNB:G\3/AMJ%CJ
M%B4Y5M/?Q!(&C)/3R^P/. !_!K_P5E^%G[/WP)_;/&N_L>>-_!ESX \7>'?#
M/Q(\.P?"GQ9HVO:7\.?'$.MZ]'JVDZ!J^@3SGPZIUS0H_$^SS"$;76552- H
M][*,/PMXD_VEE&(\/JG ^;*C4J8:M3C64/W<?=IU$X0C&3T?LYWA*-U&2E%H
M^RX4ROP_\;(YMP;B_"67A_GRHUJW#/$N'IXJ%*,Z4'/V5><\/AZ<V](M58^]
MKR2YE8_T#/VL_P!I_P"&O['WP*\=_'KXJ:@]KX1\(6<;I:V$2OJNO:KK4L>E
MZ'X4T10T;2Z[XA\0306]LJ-E)I!YAPF^OXN_B#_P7(_X*B_M7^/]:T3]E/PW
MJ/@/1K6?[5IO@SX,?"W_ (6[XZM=("[ ?$NO>)/#?BY9R%^4OX9\'>$&[G)R
M3^G_ /P52?XM?MI_\$4/V<OC[X>T[4];U?1(?@Q\</C!H^F6)7?I!\"ZWI'C
MK7(-&W,WV?PMXAU]/$A 5-OA2"Z(#Y!7\M?^"-O_  5B^!'[!/A3XC_##XQ_
M"WQ7?V7CSQVOC1/B3X$LM*UC440Z)H6A2Z-K&BL\$ZZ+X<70UDBF$LFQ]=U]
MHXV=6C?GX"X1R_!<+9SG$>&?]=^,<EXDJ45PU*2Y72HRJ03<')<RT<I-1FFD
MDVHV3Y_";PWRC*O#[BSBW_5*EX@<:Y!Q7+AB/"E64>2G&C4E3==TY<]1O]VZ
MMXPO-.,%4BN:^-I/_!8__@L/^RIK=A-\>[;Q%?Z->7;+_P (_P#'[X#GP+IM
M^#@9T36_#WAKPCXD;G! 82+GJ.M?UK^'OVL?BAX__P""9GB3]KF3P!/\&?BA
MJ?[-7Q-^+'AKPKK5S!XC&B:GI'@_7]:\#:QF"**/7]#\00P:'XCC_=[OLVL1
MPR,\G[Q:GPE_;:_X)V?\%!O#]W\-]"^('PH^+47B*S>UU7X3_$#2[?3_ !#J
M4.T-Y,_@?QQ:V\^N(6&6(M)U3:',K?=KVK]MS3;#2OV&OVK-/TVWM+'2[+]F
M7XQ6>G6MLH6PL=/A^&OB-%C11@;(T0C)!=@I8DEB3\3Q7FV"S3,,GP>*X"CP
MMFJQ=-XA>RE3]I&56$'3]ZG3BW*Z7/:2DH)1<FVC\I\0N(LHS[.>%<HQ/A-3
MX!SV/$U&GQ$DJE*-6C/$X:'*J<Z5)*"YJD7%0G'5<LVI.+_G+_X(N_\ !4W]
MMS]KG]L:+X3?'CXK:5XP\$R?"OQSXG.CVG@/P?H!;4M$F\.KHNJ_VWH.@185
MEUKF$2)&W&5=3L;Y#_X+G?M)?MU>(OBO\>?@/XYT?QO_ ,,=>&?B'X _X135
M;KX0MIOA@:J?!?A[Q#HZI\47\-&/7/\ BI_[=&!XL &T*5PH2O,/^#<:-W_X
M*(6RQMM=O@1\2'W<?*J7/P_+]>/N(WYU_1!_P<6QI_P[>\3Y(;=\4?A>XP,?
MNTUQ5<9QSO8YQQC''%?I&-P^3<*^,60X3 9-AN7-:?#<H05.,98>K."<JM'E
M@XPE+FFG;V;:YFY-NS_<\V7#OA_])/A+)\IX4X;5+/,-PI3I7BHT^'JU?FE+
M/Z*2_P!X:C[R6CYXNU[G\CO[!'[4W_!0G]G71/B+;?L1Z%XXUW2?$VK^'+KQ
MU_PBGP5?XME=1TC1=<&C*^/#GBN/1!(%&X,I7Y01MSQ_8I_P1<_:-_;A_:)^
M&_QKUG]M;2/%>F^)/#?CRPT;P&?%WP??X32G05T-#JQ32?\ A'/"IUD?V\LZ
MO*8Y"J[0K(<!OS._X-9!YWA;]L>.55,5IX@^$BJQ4,5+Z1XU!P,=3@#C)..P
MK^HKXV?$?2O@O\'?BQ\6=7@"V/PU^''CCQ[?0QJ$$NG>"]!UC7Y<#&%9H[=L
M'L2".5 KYWQ?XBP.-XGS?AB/"U!9Q.O1A+BB,[U92DZ24*D5%>^X3C!7<VZ:
M3DTE9?(?23XTR?-N,^*> \%X?\,0SJ>+X<HKB^*:XCJ5)+#KFE-14>6;K0IS
MO=\L8IN^A^/_ /P5)_X+2?#K]A.]B^%'P\TS3/BU^T+<:?%>W7AR;4VTOPY\
M.M.UD3-I6L^-[B0R2/J#.8VM_#,:17-TD327%SX;MYXG/\W\7_!6#_@M7^T'
M=:AXO^%NL_$[5?#HN]@M/@I^S?H_B?PQH:C@#^W)/AOXO+$X&-WB\MTZ'./D
MC]AW2/A-^UC^W99^-_VWOBIX0\/_  _UW5?&_P 9?BOK?Q \71^"]'\<:H[)
MK*^$&U?Q!/;))%XAU_7]$FDMUN())/ _AN2"-TE9:_O#\*_MX?\ !-KP7X:T
M;POX2_:D_9/\+>'-$L4M-*\.Z!\4OA?8:=9Z>B@;=(TK2/$.%BX&$AB"J2S*
M#N8-[F/RO*?#;"97EN%X-EQQG%7#PJXC%>QK2IQ52*_=PFJ55SE>4G[.*7+"
M*G5;G-(^@SC)>$_!'+LFR/!^$LO$'C&=&GB.)N)*M#$UL-%UH1<:-)PPN(I1
MY>9TXTTE*$+2J-RGK_+-^S3_ ,'$'[8'P2\;0^#OVR/#D?Q=\+V]Z;'Q,J>$
MM(^&OQ@\*!XRCE-%!\(^'-8V LJ^&O$'A>UFW,'_ .$Y."%_M"^!/QZ^&G[2
MOPK\(_&+X/\ B>Q\6^!O&FF)J.DZK92 \,D8DT_4HU82:3JT,L@26WE >-E;
M*%3"S_S0?\%TO$O_  3T_:<_9EUSXH_##XX?LY^+OVD?A3<>&+OPD_@?XE>!
MK_QKXJ\.Z[K.AZ-KWA,PZ%XC%QK?A^3P_KC>(FA4RQ Z'#)&4S+7%?\ !KA\
M7?$<Z?M-_ J]U"XN/"^FGP+\2?#FDL@*Z!J^NIX@T7QG*Q/4^)9?#^AE.<#^
MQ'((.*\#BSA;*>(.!I\8Y5D<N'<VR:JX8NA.G.-*HIRY9M*<*:E;F4HSBES1
MYHRBYKW?F_$7@OASC/POGXJ\,\)5. LWR*LJ/%'#%2G5HTYQE*G:OAU6ITE*
M#56,U.G%7O.+BIJQ_88.@[\"B@< #T HK\'6ROOU]>OXW/X_/SQ_X*J>'YO$
M7_!/#]KZPM1B9?@3\0-9'&<'0-!GUW\?^0.,?4YK_,/>7,45P ,AW!^[WS^F
M /\ (K_6V^(7A'1O'W@?QEX!\0VPO="\7^&=:\/:S;<_Z9IFLZ7)I6I0D#IN
MMII$;&2!C!-?Y3OQQ^%?B/X#_&3XG_!;Q-&8=<^&?CGQ-X/GD&\_;QHFK%4U
ME0O.)E*^(OFX 901P*_JGZ.F88:6"XJR6ZYZD%."O9R4X3I^[&]W:4MDGNO0
M_P!!/H3YSA,7E7B'PJY156O!5H1<DI252E4PSE"+:D^635^6+=I+74_9[_@O
MB%\7>/OV+/C=I,YN?#'Q;_8T\$'PY=VO/VTZ)J^L^(#P"<!E\<Z$^"/X^G-?
M,WA P^-?^"-?QKT72I,ZA\$?VZ?AO\6O$MMR/L'A;QU\-;;X2Z%K!((.'\1;
ML], ''6OISQ2(OVY_P#@BWX)UK2]^L?'#_@FCXP'AGQ?9LX&IWGP0\9+AM81
M-H8>'SX731'9BV?^+=^)A_" /@3_ ()_?%WP5X7\9_$CX ?&/54T;X'?M;_#
MH?!#QYKUX0-)\%>.5UE]8^%?Q(UD&2%';PKX^=UB\Z18T\+:]XAEE)2-A7Z#
MDF';X1>"Y&\XX&XNE*5-7;E1^L3JN2BDV^;#U.96C)N4>5/F::_7>&Z&)P_A
M[+)5"4LX\*N-)5)TH).<UD'$\\7SQ@DW/GX?S^56#C&<IR@U!N=I+]Z_^#6G
MQSID6J?M?_#F>YMDU6ZM/A#XSTBTQF2\L-OC[1=8(##!\F2/1'/)RVMK@,#7
M]</B?78O#?AS7O$[Q&;^QM(U75VMP>3_ &9ILDQ5>XW&/@\D;NP.3_FH?L=?
M'WXI_P#!+C]NW3_$'CKP]K.FZA\//$6H_#7XY>#+,AM0USP-K>V36)]"+-_Q
M4"AET'Q;X*8,J^,QH/ADJ\8*D?Z//PM^)_PV_:'^%/A_XD_#GQ-I'C#X?_$#
M0!J&B:YI$BSZ;J-A,C(9XR#N"'<ZE61",'"D8S^!^,F2RPO%\>).64\FSV5"
MHY1]Y)Q=)58.U[<T8SE!MI.[U;O?^1_I1<)XS*O$>EX@.G*IP?QJ\-BU7C[]
M.,H>P5>DYI.--RIPE."E.*G"4FI-QD?YPOP:\/\ Q"_X*M?\%$?"6@_&?X@Z
MAINN_'OQSXGO?$6N1W9U!?"/A;0]&U_QU_PAG@C^W58111>'-#'AKP:^"(X]
MTI1E5J_K_P##/_!O+_P3<T73+>PUKX?>//&&H6\8>Y\0:]\4/&::G>LP!VR#
MP_<^%]!8DG^"S&WC=GDU_,W^W/\ \$W?VL/^";O[1UU\9/@#IGC&Y^%6F>,-
M0\9_!;XQ_#^T_M74? ,;KN&C^-PH<Z#%X921/#BMXK4^#_&<1",JN\D0]?\
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M87G)_:6\4X/8$_#/X1_X5S/_  <_:9?ZC^RW^SY%I=CJ.I7!_: A*BSLSJ+
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MPTZ$IK#K$4%4EB)49<B:I<D:TG)4W6T3=O=_G?\ ^#< 8_X**V?O\"?B2?\
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MW^-\/Q$L=%MO&O@+Q/H]_P"!OC3\-M0 ^P?$'X;:P1-J^F(""'\20LB/X/\
M,0P.3)#<))#(Z/Z+^VO^R9X8^'R6/[37[+NJQ_$7]BKXO:HP\"^*;-2VH_";
MQ-("NM_"#XF:))&6T'7O"V28V\5<^*_"F5\P2QEG_1+_ (*H?\$0_B/^RUKG
MB7XY_LO>&]<^(G[.%^=3U;6?"6GQ2Z[XX^#+)\TBM"V)]>^'8&]_^$F($G@Z
M$%O'#20%_&C?C+\ _P!ICXK_ +.5WK\G@/5M+U3P?XSMWT;XC?";QGI:^,/A
M-\1=.V$-I'C3P/K4B:!K),<DBF2)(_%^QWB20JS)7]JY;F.#XB:XOX/S2-YT
MXQXJP\Y*/M7))N$Z24N6K'FE"-3EDU%RA/GC9Q_U"R/,LDXZ4?$KPVSBA+-Z
M]*G'BWA-RBHXNFZ?*XRC;W>(8\T_95N2I%TY.G-5*<HN'>-\6O!OQ_\ !WAK
MP7\>]33PI\4O!N@:9X7^'?Q_DLSJ>FZKX9T9C_87P\^,X1O^$GUK0O#:!X?!
MWQ*\-J_B[P<DR^%?&J^+/!A:;POZ_P#LD_M_?M??\$V_$US9?#7Q5IFM> M<
MNFN]5^&GB"^_X33X2^*U<HSZSH6NZ!XC*:%KSE$\SQ#X6)CFVH)(Y$4J?"?'
M%S^RC\4%GUKP5:>*_P!FKQ?<)]JO? &K_P!K?%;X)OJ0"!6\%^-HU7XE^!?,
M82N_AKQ/X-\6QH BKXS"@$?,NIV::9=7-A#JMAJ$&>;O2KP-IUZ,YR.8\^X(
M&,\>WTRR#*,ZP4L)C\G<LIJ/F:G'VG+)ZNW-SJ"4GS)TVHJ3<H\K=E^A0X-X
M;XDR:64YUE#>3SE*4N&>)5S^SG--S=*5ZBII2G.<?8U(1C-N4%!R<5_9W\-?
M^#H#X"ZOHT"_&;]G#XG^&M<"A;I?!EYX4\;:#=N, E;K7KCP=*@]%,9(/1MN
M5K,^(O\ P<U?L_:/I=]<?!/]E[QYK_B2=,6D_C6X\'^!M-9CQNEET&X\6Z\P
MXSAK1<'HPX%?QC1Q6C@[KAD..A3_ /7_ #KO?AI\*?B+\8_'.B?#CX2^#_$7
MCSQQXAN&@TSPWX9LUN[^[CC4O+)([MMCBB4,SR.RJJJS-@ U\5B/!KPYRZ,\
M3B^:C3CS5)4WQ#.G2Y4G)IP=2$&N5-.%NEMD?E&+^C)X,9,YYOF&#Q&&R5<U
M25.7%->CAX*-YR?LG6HP=."4OW;]WDAROW4S^B3PI_P<8?\ !0CXF^-O#7@'
MX?\ P#_9S\0>+?&?B/3?#?A/PI!X;^)%_J&H:KK>J^3HVEEO^%B* =@RT@8*
M",C %?VF_#!_'=Q\/O!D_P 3;;PU!\1KKPYI4OCB#P9_:H\*VGB=M.0ZVGA\
MZWMULZ$-6W"S^T?Z48O):4[C,Y_$'_@D3_P1[T;]B+2K?XY?'2TTGQI^U)XB
MTA;"Q33T74O#?P=TC68T&LZ%H+EXHM;\2S(H_P"$P\62N1Y:GPCX,5+*.YN/
M%O\ 0(8L."7"KA?D7...N!T ST!QQ]*_EOQ'S#A/$9O+"<(Y=[#*:7N^UYG)
M5)I>]RR<^:4%)*T[IRFFU[JO+^!?'+//#7%<04\D\,LFCE.1Y%>$^(85:TWQ
M%5YK2G&-6I."IPY'%M4X2FWS_"U>*+2-+BE,\5A:I-_?^S =?8KU]QT_*M7
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MM;3XA^'O%G@Z_1L<J7\.MXP5@/4KR.<=J\5T_P#X-G?V_;VZ$-]XZ_9RTVW
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M10 4444 %%%% !1110 48'H*** $P/0?D*,#T'Y"BB@!:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ea028973301_ex5-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028973301_ex5-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" *D# 2(  A$! Q$!_\0
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MKGPKJ7B==2TK48-,LK=M6\.Z+KT&GZ;>1-;0>L_\%^_^":7[1G_!/G]L>_\
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M\/?B7X>L]9T^:&>!]0T/46C5-;\)>)+6&20Z5XJ\*ZH+G0_$.E3'S;+4[.=
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M.E?$K3=+N[&TTY]-L+-#(\_X)_\ !/'_ (-A/VY_VE_'_A_6OVJ_!^K?LE_
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IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ea028973301_ex23-2img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028973301_ex23-2img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !L &P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBB@D $
MD@ #))X  ZDGL!0 5Q.M^.]+TO47T'3;34O%?BB...67PUX:BM;J_LH9D$D$
M^MWM[=Z?H?AJWN81)-8R>(]6TK^U5@GBT==0NHC;GY_^-7[17@WP-X.NO&?B
M7Q7<>#/AB)9;*QU[2A'-XW^*=^D;-_8OPKL6;?#I-R08Y?'$HA$]F)M0\/7&
MEZ5-IOCR/\&OVBOVU/B]\1[1/!WAG3[KX*?"34;9]3TOP=X>FN[/5O%6F:C-
M<+_;GC/Q.?)U;Q/<ZW+'<W-\YDATW597-W?0ZM> :K/YN,S*CA4U?FG:ZC&S
MDT]GK[L(/6TZGQ?\NX37O'H83+ZN)=[<L+V<I744UNM/>G)+>$/ATYYP?NG[
M+?&']M?X9?#&6[L?&OQ@T/2-:M&D67P#\$]-M?B5XWM[FWRK6FH^,O$5H/ ^
MFS2'_C\T?5?#>D7UK(5CMM8GCCDN7^"O&O\ P4M\-/&]SX8^ ?BOQ;I,TYCA
MUWXQ_$OQ-K.CZA<J[E_-\#6R7_@^UN"BB0P:9?QP6[EXX;9(HE+_ ) :5J=[
MHNHV6K:=*L%_I]Q'=6DSPP7"Q3Q-NCD,-S'+ Y5@"!)&P! 8#(!'[6_$2TUS
MQ];_ !_T/P!XHM_$>H_M)_ SX._%OX:_ G6+C4(;0:3/!INH^*M5^'YO7DTJ
M[\7:!?>'M=@L/".EKI]U):W/G++=S:"-.;QEC\5BU4<)JER6M",%6F[PJN'O
M596;E.FJ?+3I)WFG%22<7ZTL#AL*Z:G!U>:]YRFZ45RRIJ7NTHNRC"HZG-4J
MM6BU)QNI+Y9NO^"CWC&29FL_V<_V4K>W(VI%<_"W5+N81D\QO/'XNLT=2,9"
MV\8)&<<X'H_P]_;^\:^(KB[2T_9*^%/B6[T>QEU?4O\ A4.D>(_!'B:QTBS5
MC>ZG;WVBS^(M<L+*Q5@]YJ5NKVVGQ,'NWB25'K\K+ZQO=,O+G3]2L[K3[^SF
MDM[RQOK>6TO+6XB8K+!<VTZ1S031L"LD4J(Z,"&4$8KZ7_9S\;ZW\#U\2_'S
M2].CNY_#.I>"_!6CK>6X:SO=1\5ZX^OZYIS2RQR1F#5? /@7QGX;U!XD::UM
M_$*RQO#<&V<\-+&XIU$IUYQBKN;5*C)PC%-R:BZ$;M::7C?:Z;1V5<'AE3;A
M0A*3LH+VE6*G)M**YE6>^NMGWLTF?J=\-O\ @I=\%M6DM;35]5^+_P &+V0K
M)(=?NU^-_@#[3A!_Q-=1U9;GXEM:%V96MO#_ /84;11B47%K*VVOT;\#_&ZP
M\4Z(GB+3[OP_\1_".523QY\([Q_$=I:/M#,OB3P,LU[XN\.7>Z2.,:9I3^-;
MBV19[S5YM)MHWV?SV_&SP%I/P8T/XF^*_!$.GZI\*/CO#\/=0^#4VKZ1IFK0
MVGAOQ:^O>+M;&GQ:G;7\&F>*OAW-X<_X0*^N8#'KNEV7B.&4SVLNI9'Q_P##
M_P")?C[X5>(;;Q7\.O%NM^#]?M60K?Z+>26_VB-'$GV74+4[[+5;"1@//T[4
M[:[L+A<I<6TB$J?0AFN(PTU3Q"C4TNW37(TN9J,E%RE2J1G!*I%I4FXR6MWI
MPRRRAB(.=!NGV51\R;LG*+:4:E.4)-PDFZB4HNZT/[0-*U;2]<T^VU;1=2L=
M7TN]0RV>HZ9=P7UC=1AVC9[>ZMI)8)E61'C8QNP61'1L,K :%?BS^RW^WYH?
MQ+UFVT'Q[=:+\*/C+JDUM;VWBB")[;X4_%F^ CMX['QSH_F%/#/BN_CCAM;/
MQ58RQ7#7$=K;QWQTR"W\%:K^O7A?Q9!XB^WV%U93Z'XFT1H(O$'AN^DCDN].
M:Z$ILKZUN(L0:MH&K+;W$FBZ[9C[->BWN[*XCL-;TS6=(TSW\-BZ6*@ITY)W
MT=KJSM=QE%^]"26O++=>]"4XW:\3$86KAIN-2+5M==4U>W,FO=E%O3FCLVE*
M,):/K****ZCF"ODK]HKXU>#_  +X-\5^)?&ES(/ACX-G72M>L;.:-+_XI^-Y
MXR]A\*]%)<&YTJ)AYOCF5/\ 0YUBN/#VH33:5I?CO38_?_'>M:CIFE6FFZ"\
M<?BCQ7J47AGPU-+$DT-C?W=K=WM[K<\$H$-S!X:T/3]6\1R6,TD"ZJ=*71XI
MXKK4+<G^8S]N?X^6WQ9^)J>"/!EU,/A+\(3>^%/!T7VE[E?$&JQ7#)XH\=7]
MPS.^I:EXDU2*5DU6XDEN+^Q@@U.<IJ&J:F9O,S+&+"T7:SG+W81>SDU=<R_D
MC'WYK[7N4]IROZ&7X1XFJKW4(^]*2W44[:/I*4O<@_L^_.UX1+]Q=^+/V\?%
M_P 1->\0^/+*'XLVNB3S_!7X,K]IL-&O-*TJ[M+W4O#'AK4+J(:5#?0: MZ=
M)T>-EU3Q1J\-UJFJWUC#9M]N\2CU?5_BII6L>#?B#/JES\0? 7AWQ/JOA'Q+
MK;W4NM)I'@K3M3\2>)_AUXKEOLWTMA9:3INN:AX3FN2UYX?UNVD\-^4^E:Y&
MV@>&:9J>HZ)J5AK&CWUWI>K:5>6VHZ9J5A<2VE]I]_93)<6EY9W4#)-;W-M/
M''-!/$ZR12(KHP90:]!_:T_X*!:3\,O@[?\ QH_:)TSP/:W/B-+GPOHFE?#S
MPSH?@_XT_M2^+-'BL+FYT/4?$\=M?OHW@[1Y)=(OOB?XZLM)L]*LK673-)73
M/$7B2^T'1:^9HJ6+GR)5)8BHY<_Q3CB(R;?-4DY6I2I-I\]G!0248QFE&I]'
M5MAH\WN*A!1Y-HSH25ERTTHWJQJI.\+J;FVY2E!N5/B;31+B;1=;\5:C>Z+X
M8\%>%X8[GQ9X^\9:YI7A#P'X5MI21#+XA\7^(;O3M"TR2Z*M'IUC->_VEJ]P
M!9:197]Z\5L_R[\<_P#@L9^R=X5@\'^%1XZ^)'[1M_\ "[38=#\'+\$/ VA_
M#+P5H5C8WDUTNFZ?\:OB5I]C\2K\QWUW?7RS_P#"K-=T?[8YN-,U:XMC:R)^
M,7Q0UG]N7_@I)J4/CGQ3:V?@[X)>&7NI?!'A^ZU&3X=?L]?##2'!6:7PKI>K
M7EU<ZS=O$ GB/QU+'XL\8Z]/'YWBGQ'?SI$(_FCP;\*_@QX,^/6D>'/BS\7O
M OC+X:^&]%N_%GBW6?A]>:YJFBZ_>:3;7EU'\/=$U5M-TV74-1U>[MK2W:]L
M#%9S6-W)'9ZC#J6(HO8PV78*@JD:M66*K1@Y5:-%S<%R6DH<M->]+FMRJI5C
M)RU5-)-QX*V*Q-5P<(JA3<K4YS4>;WKQ<N>>RY;\SITW%1TYW=7_ &?TG_@J
M_P")?BM+<Z[\//\ @G;\5?B+;M>.-5\0:C\</&GC^YF$$8$D$VN^%_@CX9L(
MM5$*QJC745W@A8UL)040:EA_P63^%&CR:C\-_C)^S+^T[\#]/EN;6\U31O#O
MQ>T?QS##.BO+;WE]\)O'/PY^#QNKF.3RI+2:Z\<VS["[)(C*&D_*34/^"EG[
M0]EXE@G^'\GA#P'\.](ECMO#GPNT[P?X=N?#UCH-I(JV6EW=_)IT>NR2?9(X
MX;RXTK4M&B:1II-/M=.1TBC_ $%_;$L_!W[2W["VC_M#/HEIIGBW1=!\+^+]
M'N@8OM6G/J&N:=H'B[PP^H;3-=Z1YMYJ+VMO(R&?4-/TRY,<,QEB:JE*E2JT
M(XG+L-"CB:GLHSHU:DJM.<]HU6G%2O=<SBY1WLY<OO$93J0J.CC*\JE&/M'&
MI""A*,=W!-2:M;W>:*>VBOI^L_PQ_:A^&'[77@;P5\-?@%\>-$^*L'@"?Q;K
M?A?X,ZYIU]\/_CEHD?BPZ5?^([>U^'6OR20^-4BGTA=3FM_A/XC^)4.DFZU2
M]O+RWMIIC#Z)\,/A#\0/C!XNL?!7@7P]>ZIJUU?P65Y,\,T.F:"D@N'FU'Q%
MJ!C:'1]-LK>SO;J[N;K;MBM)TB2:X"0/_(YX1_8O^)]CX9\,?%#Q]\0_AK^S
MQI&L3V>H>#=0^)?C*Y\-^*=2=4@O['5-!TO2K&^O[>: -!=I]JN=,U.S3R[T
MVT<!BG;^@S]ES]KGXZ_"@>"M-_:W^(7@[Q-I'B2TB\*?"[]O+PCXG;Q#X>U1
M?$%O)I-A\.?VI[VXM+27Q7X'\7632>'8?C!JVG7%YHT]S!8>/=<\6^'Y(;SP
MIRXK 8252+P^(=1J2@Z#FW*:IJSIX>O."A*<8KE5)SF[+EB^9)&M'%XB%.2J
MTHQ5G)5>2R@YNZJ5J4)<W))OFE-0COS23BVS]C_BUI'P5\.>$O OPR\-1Z)X
MG^%OA^[\36?B3]HS3KO[7XMU/XN36<<NN0^&= -[#-_PB&DC2=+MK'PS+:2:
M5X@TK4[/6HO$.GWVIV/BIOIC]A+]K[4_%EWX9^"?Q&\0BV^(&CAK+X'?$G6)
MI9/MJRB$S?"7QS<Y:?5/#WB!+6"UTI[@S7,=U#8)821^(M*\)7%O^5?Q+.F6
M>L_\(_IOA#7? LVB2W4>O>'-7\5-XFLK7Q+/Y":K)X>#:98/IFA2"UMDTV"\
MO?$VIS645M->^*M:7[-,G%Z+::M?ZQI-CH,5Y/KE[J5C::-#IYD%_+JMQ=10
MZ=%8F(K*+M[QX5MC&RR"8H48-@UY\,94H8A3IQC%+EIRI0YHQE"-H^SUC&=X
MM?NY3BZL*G,W*3<HOJEA85L.X3DVVI3C4GRN492NW4=I2C::?[R,9*E*G9*,
M4E)?VI>%?$D'BC25OTMIM.OK>XGTW6]%NWB:_P!!URQ81ZCI-Z86:)Y+>0K+
M:W<#/9ZKIT]EK&FS7.F:A974W1U^<'[&?[1Y^+W@'P[X_P!5G0>*M/OM#^$W
MQPM@51KO7Y?)L/AI\3FMUR3/XAEFB\+:T\-M"]W>:@&GFBT3P-91C]'Z^RP]
M:->E"I%W4HII[735TVEHGHU)+:<9I:<I\E7I2HU)4Y*SC)IK>S3LTGU6J<7U
MC*+WN?GS^VO\89?AE\,OC!XVL;QK76=)T33O@CX!D60V]Q;>-_B3:6GB/QEJ
M5H5.7GTWP./#>J:/><O;7VCZQ;1HB3W#R?C;'\!I?B#\-O 7P^\!?&/X5/XY
M\/V<^M>*?@UXMNT\!^+F\=>)99+^6+0?$7B>RMM(\0ZC%X<E\.:!J.D6NOV5
MK87NA3B6W-ZET]?2O_!3KQK<OX.^!WABWN'$?BWQ%\4_C%?']ZLMU9ZSXB%O
M\.[J1]RAI;+PM?W>GQ[T:2WMHK:&)HXT*O\ DGX@\0:SXJUB]\0>(=0FU76M
M2>*74=3N1&;O4+B."*W-Y>RQHAN[^X6%9;Z_G\R]U&[::^OY[F]N+BXE^7S/
M$QEBIPG!U(QA"-E.4+>T?MIRC*-_>:]C%<T90<8V:V/H\OP\EAH2A-0E*<I7
MY8SO[->R@G&5O=_C2TE&2E*Z>YZ'XM^#GBKX3>(+C3_CI8W?PGT?P_H'B'QW
MXWU;7XX7?PY\-O!>GWFL^+?&D=O!/(NIZ=:Z5I>K)H<EG-)!XDUJR;0](GN=
M0;R1^%MU<:1^UGXP\=?M_P#[5&G/X>_9S\ 6-QH7[.GP8NY?M6EZ#\,O"VKW
MEOX;TV]LE98]:FO-8N9I-11C&_Q)^)VN>(_$.JQ?V?J,-KJ/W!_P4=^)?BZ+
M]D'2?AY;:U<-XJ_:>^+?PV_9A\/7=S+,S67PM\(W\'Q)\=Z=:.!N53XTNO@Y
M;W"B9&ETK6-;LGWVU_+$?AG_ (*07_@[P'\//V<_V?Y=4U3P5\+]4U>=M>N/
M#VEQ:SJ%CX3^&^DZ1IVF6D6EO>::FHRS76NP7*)-=Q1M?6$=_/YLENJ2:86"
MITZ,*//">8SJ-U%:5:G@J%^>,'%+]Y5E&:O%)M*-K/:JTG.=6=7DG'!QBE'5
M4IXFK:TI*3?NP4H:2;M[U]-_'_AW\"_V^?\ @L;X\N-*^!OA;2=,^$6A^)['
MPM8V.N^//#G@+X7>!IWAAETQ-9;4]0M=4\7^)(M/N;6XN$\-^'O$NM1+=I!H
MNB6EG/;V=?TB_M+?\&W>@?#_ /X)?> ?V??@4_P,U[]KZ3XV^$_B'\5/VC?B
MO?V?@,ZS:'PIXOT_Q!X'\&>++S1]5UK2/!-A<7.A1Z%X0S#'K!TV^\4:M$FL
M3S1Q_@9^P)^SK^Q'\8OCM\$]=^#7Q&^,-A\0?A?\6_A1XZN]"\;-X9AU#4;7
M0?'_ (>OC=OI%GH\=M=::UY;PV4T^A:Z)-*DOK07Y+W-H9_ZF_\ @[,!/_!,
MCP*J@EF_:[^%:@ 9))^''QHP  "22> !R37T&$J4'&=&C3G15!QC*G4I.E)<
MR<HR:;?-SI.3FY2<G=MM[>+BHUU4I2J5(S59N49PDIIN+LT[6MRMVY;125DD
M?R[>,O\ @W _;[\&>$?%/B^?QM^R3KT'A7P[K?B2?1/#GQ_L[[Q!J\&AZ;<Z
MG-INAV5UX:L+:\U>]BM7M].M9[ZTBN+N2&)[F%7,BX/QT^(?@SX)^$/V5?V*
MK_5M/OI+?Q-\';CXZW,$D1TW3/#.G>)]$UK4["^\QO(3_A(=:,VN&&Y8O;Z'
MI\-Q>0&+5[21_EWX<^";/]B;X>Z9\=_B/HD>J?M%>.[&YMO@1\,-0MGFD\%V
MMY!]EN?B#XOL!B:*_C@NA%IVD.J7,+7":>PCU.[U"7PQ)\/_ /@E+_P5._:L
MW_%/PS^R5\;O%</CR[;6T\;^-[#3/AY8>)9M5N"5U&RU;XEZKX0LKVUNI&'V
M2:RD:R^S^5]E(M5BQA.$<?5C)2MAL,ZG)-/^+B'"5/GAWIX?F=I;3K*T6XP<
MGT0G+"4Y*;BZU90NFN7V=%-3Y9*[]^K97CO&F]5>:2]!_P""MG@'Q\/B3X(^
M([VFH7WPW;P79^%[2_@CEETW0/$=MK.LWM]8WPCWPV,^KVM]IUQ9W<XA.IBV
MFM(3*=)(70_9QOI?#?\ P34_:+O/B3-)!X.\077B[3/AM;:G*8_MNM:CH>F:
M;8'0TFWF6U;QRD<T<5K&46_TW7+LA3'=3+^BOQ=\._M"_P#!.C]GKX;^'/V]
M?@W\3OB)8>)IH/#&M>)[?X<'4O &@Z/-;A+3PGXG\=:Q=2>$_&GB.**VG2QM
M9I;#4M;M;6>6Z1UMH=4U3XC_ &T/A)I_[0_P*\._'C]G;QY/K_PP^'6@G_BT
MFF00Z?X9T#1]*@2/5+[P]X?L;&QDT;Q'X?M&:77]*UJ&:Z.CQR/IMS:06UMI
M^I>;"=14L+@L13=&C#$P5/&<DU"HJ-64Z<8QE&,J<ZL_=YZBC%QNTI-W?=)0
ME.OB:,U4J2HR<L.I1<H.I!1FVXRE&<81][EBW).R=DM/M3_@E=^U)8_M)?"
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M/5U9M>BII-_>TC+*D_;57T5**?JZFB_!L\]K]ROBC>37G@[]F*\N'MGN+O\
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M-AJ%A<SV5]8WD$MK>65Y:RO!=6EW;3*DUO<V\\;PSP2HDL4J/'(JNI _T#_
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M+:1<327,FCVUS#>Z.+F90LUU%I.J07VG6]U, OFW-O;13RE(R\C&-"OZ=_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>May 07, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001807166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">AMESITE INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>May 07, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">4,836,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 4,884,607.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 674.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), based upon the average of the high and low prices for a share of the registrant&#8217;s common stock as reported on The Nasdaq Capital Market on May 4, 2026.<br/><br/>Pursuant to Rule 416 under the Securities Act, the shares of common stock offered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions.<br/><br/>Represents the resale of (i) 418,118 shares of common stock, (ii) up to 696,866 shares of common stock issuable upon exercise of pre-funded warrants, (iii) up to 1,811,850 shares of common stock issuable upon exercise of Series A-1 warrants, (iv) up to 1,811,850 shares of common stock issuable upon exercise of Series A-2 warrants, and (v) up to 97,561 shares of common stock issuable upon exercise of placement agent warrants.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>May 07, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 4,884,607.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">674.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 674.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea028973301ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea028973301ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea028973301ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ea028973301ex-fee.htm">ea028973301ex-fee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea028973301ex-fee.htm": {
   "dts": {
    "inline": {
     "local": [
      "ea028973301ex-fee.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2025": 1,
    "http://xbrl.sec.gov/ffd/2025": 5
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 20,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028973301ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028973301ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028973301ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028973301ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028973301ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028973301ex-fee.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001213900-26-055211-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-055211-xbrl.zip
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MP!\I43F/PF8,_HEDCR)HVM7=BKH$L'TW"*4RHIK R>6 >N*3%P2 5:T3(08
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MDPBU2ZE?2U3^ U!+ 0(4 Q0    ( /N*K%R[RBHV%PL  #,V   5
M      "  0    !E83 R.#DW,S,P,65X+69E92YH=&U02P4&      $  0!#
)    2@L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ea028973301ex-fee_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807166</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-07</startDate>
            <endDate>2026-05-07</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807166</identifier>
        </entity>
        <period>
            <startDate>2026-05-07</startDate>
            <endDate>2026-05-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0001807166</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">AMESITE INC.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_1" id="fee_012">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_013"
      unitRef="shares">4836245</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="USD">4884607.45</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="USD">674.45</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_017"
      unitRef="USD">4884607.45</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_018"
      unitRef="USD">674.45</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_019"
      unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_020"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_021"
      unitRef="USD">674.45</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_022">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), based upon the average of the high and low prices for a share of the registrant&#x2019;s common stock as reported on The Nasdaq Capital Market on May 4, 2026.&lt;br/&gt;&lt;br/&gt;Pursuant to Rule 416 under the Securities Act, the shares of common stock offered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions.&lt;br/&gt;&lt;br/&gt;Represents the resale of (i) 418,118 shares of common stock, (ii) up to 696,866 shares of common stock issuable upon exercise of pre-funded warrants, (iii) up to 1,811,850 shares of common stock issuable upon exercise of Series A-1 warrants, (iv) up to 1,811,850 shares of common stock issuable upon exercise of Series A-2 warrants, and (v) up to 97,561 shares of common stock issuable upon exercise of placement agent warrants.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
